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ABSTRACT 
 
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor 
involved in the metabolism of environmental pollutants including halogenated aromatic 
hydrocarbons, for example, 2,3,7,8-tetrachlorodibenzo-ρ-dioxin (TCDD).  The AHR and 
its downstream target gene cytochrome P4501A1 (CYP1A1) are also involved in 
cardiovascular development.  AHR knockout (KO) mice are hypotensive, with cardiac 
hypertrophy.  Additionally, CYP1A1 is involved in the production of potent vasodilator 
metabolites from omega-3 polyunsaturated fatty acids (n-3 PUFAs) metabolism.  Thus, we 
hypothesize that the AHR and its downstream target gene, CYP1A1, both contribute to 
normal vascular reactivity of blood vessels and to blood pressure (BP) regulation.   
We generated mice with conditional deletion of the AHR from the endothelium 
(ECahr
-/-
), to elucidate the degree to which loss of AHR contributes to vasoreactivity and 
BP regulation in vivo.  BP and heart rate (HR) was assessed prior to and following 
angiotensin (Ang) II injection, or chronic treatment with an angiotensin converting enzyme 
inhibitor, captopril.  Vasoreactivity was assessed in aorta in presence of perivascular 
adipose tissue.  Immunoblot was used to assess Ang 1 receptor A (AT1R) protein 
expression in the aorta. 
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We used CYP1A1 KO mice to determine the degree to which global deletion of 
CYP1A1 contributes to vasoreactivity in the aorta and mesenteric arterioles, and to BP 
regulation.  BP and HR was measured ± nitric oxide synthase (NOS) inhibitor, LNNA.  
Vasoreactivity to eicosapentaenoic acids (EPA) and docosahexaenoic acids (DHA) were 
conducted in aorta and mesenteric arterioles.  CYP1A1 WT and KO mice were provided 
n-3 or n-6 PUFA-enriched diets for 2 months, and BP and HR measured ± LNNA. 
Endothelial NOS (eNOS) and phospho-eNOS protein were measured in the aorta of all 
diet treated mice.    
Our data showed that ECahr
-/-
 mice are hypotensive, associated with reduced 
responses to Ang II, and reduced aortic AT1R expression.  Moreover, CYP1A1 KO mice 
exhibited elevated BP compared to WT mice, with attenuated vasodilation to EPA and 
DHA.  Further, supplementation with an n-3 PUFA-enriched diet normalizes BP in 
CYP1A1 KO mice to WT levels.  In contrast, an n-6 PUFA-enriched diet increased BP in 
WT mice to levels seen in CYP1A1 KO mice on standard chow.  Phospho-eNOS protein 
expression was reduced in aorta of CYP1A1 KO mice fed an n-3 PUFA-enriched diet, 
compared to WT mice.  
Taken together, these data suggest that endothelial AHR and global CYP1A1 have 
a physiologically important role in the regulation of vascular function and BP, and involve 
different mechanisms.  The clinical implications are that n-3 PUFA-enriched diets could be 
recommended in the treatment of hypertension in humans.  Additionally, AHR antagonists 
and stable analogues of CYP1A1 n-3 PUFA metabolites could be used in the treatment of 
long term resistant hypertension. 
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I. CHAPTER 1 
Introduction 
The aryl hydrocarbon receptor (AHR) 
AHR signaling pathway  
The aryl hydrocarbon receptor (AHR) is a ligand-activated, basic helix-loop-
helix/Per-ARNT-Sim transcription factor involved in the adaptive and toxic responses of 
xenobiotics (Mimura and Fujii-Kuriyama, Feb 17).  The AHR evolved about 500 million 
years ago and is evolutionarily conserved from invertebrates to vertebrates (Hahn, Nov;  
Hahn, Sep 20).  Several studies have demonstrated that the AHR exists in an inactive 
cytosolic complex sequestered to two molecules of the chaperone heat shock protein 90 
(HSP90), the co-chaperone aryl hydrocarbon receptor-associated protein 9 (ARA9), and 
p23.  Binding of HSP90 to AHR is thought to mask the AHR-nuclear localization signal, 
and this interaction is necessary for cytoplasmic retention of the AHR (Kazlauskas et al., 
2001).  Therefore, the ARA9 maintains the AHR in a cytosolic localization, decreases 
AHR degradation, and increases its ligand binding capacity (LaPres et al., 2000).  AHR 
mRNA is constitutively expressed in a large number of mammalian tissues, with the 
highest amounts of expression found in the liver, lung, kidney, heart, and placenta (Dohr 
et al., 1996).  
In response to agonist binding, the AHR undergoes a conformational change, 
translocates to the nucleus, dissociates from the HSP90, and dimerizes with its nuclear 
partner, the aryl hydrocarbon receptor nuclear translocator (ARNT).  The formation of the 
heterodimeric complex leads to its interaction with dioxin-response elements (DREs) 
upstream of target genes, inducing their activation and transcription (Fig. 1.1).  Once 
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transcriptional activation has occurred, the AHR is exported to the cytosol where it is 
degraded by the ubiquitin-proteosome pathway (Davarinos and Pollenz, 1999).  DREs are 
located upstream of both Phase I metabolizing enzymes (e.g., cytochromes P450 (P450s) 
1A1, 1A2, 1B1), and Phase II metabolizing enzymes (e.g., glutathione S-transferase and 
UDP glucuronosyltransferase).  The AHR is activated by halogenated aromatic 
hydrocarbons (HAH), including  2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and the 
sustained activation of AHR, has been proposed to account for its toxicity (Fernandez-
Salguero et al., 1996).  The AHR has been shown to mediate the toxic endpoints of HAH 
exposure, including teratogenicity.  For example, in pregnant mice treated with dioxin at a 
dose of 40 μg/kg body weight at gestation day 12.5, fetuses that were AHR-null were 
insensitive to the teratogenic effects of TCDD.  In contrast, all wildtype fetuses suffered 
from cleft palate and hydronephrosis, suggesting that the AHR is involved in 
teratogenicity (Mimura et al., 1997). 
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Figure 1.1. Schematic of the AHR signaling pathway. Exogenous ligands bind to the 
AHR in the cytoplasm and induce a conformational change exposing the nuclear 
localization signals, which facilitates nuclear translocation. Once in the nucleus, the aryl 
hydrocarbon receptor nuclear translocator (ARNT) binds to the AHR and a 
transcriptionally active heterodimer is formed that can bind to consensus regulatory 
dioxin response elements (DREs) located in the promoter upstream of target genes, 
such as cytochrome P4501A1 (CYP1A1). After transcriptional activation has occurred, 
the AHR dissociates from ARNT and is targeted back to the cytoplasm where it is 
degraded by the proteasomal system. (Abbreviations; ARA9: aryl hydrocarbon 
receptor-associated protein 9; hsp90: heat shock protein 90; AHR: aryl hydrocarbon 
receptor) 
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             AHR in cardiovascular development and blood pressure control 
The AHR is necessary for cardiovascular development.  In addition to its orthodox 
role in the metabolism of xenobiotics, recent studies demonstrate a functional role for 
AHR in vascular development and homeostasis, in the absence of exogenous ligands.  In 
patients with cardiomyopathy, the expression of the AHR mRNA and protein levels were 
highly upregulated in the left ventricle, suggesting a potential pathological role for the 
AHR in heart disease (Mehrabi et al., 2002).  Moreover, the generation and investigation 
of the aryl hydrocarbon receptor knockout (ahr
-/-
) mouse by several laboratories has shed 
more light in this area (Fernandez-Salguero et al., 1995; Schmidt et al., 1996).  The ahr
-/-
 
mice exhibit a reduction in liver size due to smaller hepatocytes, which results from the 
persistence of the fetal ductus venosus (DV) after birth.  The DV shunts blood from the 
umbilical vein to the inferior vena cava in the fetus, and rapidly closes after birth.  The 
patency of the DV greatly reduces the portal blood supply in the ahr
-/-
 mice, and the 
failure of this vessel to close is dependent on AHR expression.  Further, studies in which 
the AHR is genetically deleted solely from endothelial cells (ECs), versus deletion solely 
from hepatocytes or KÜpfer cells, demonstrate that AHR expression in ECs is required for 
closure of the DV after birth (Lahvis et al., 2005; Walisser et al., 2005).  It has been 
suggested that the failure of the DV to close in the ahr
-/-
 mice may result from the failure 
of this blood vessel to adequately constrict (Fugelseth et al., 1998; Lahvis et al., 2005).  In 
addition, the ahr
-/-
 mice also develop cardiac hypertrophy and fibrosis, correlated with an 
increase in size of cardiomyocytes (Thackaberry et al., 2002; Vasquez et al., 2003).  
These studies highlight the role of AHR in cardiovascular development and homeostasis. 
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Studies show that the AHR also contributes to BP regulation in addition to 
cardiovascular development.  Eight month old ahr
-/-
 mice were demonstrated to be 
hypotensive using invasive catherization of the carotid artery with a 1.4F Millar 
micromanometer (Miller instruments, Inc, TX) connected to a heart performance analyzer 
(MicroMed, Louisville, KY).  The hypotension was associated with a decreased cardiac 
output caused by diminished stroke volume (Vasquez et al., 2003), suggesting a role for 
AHR in cardiac function.  In another study, three month old ahr
-/-
 mice were also shown 
to be hypotensive (Zhang et al., 2010).  Mean arterial pressure (MAP), systolic and 
diastolic BP were significantly lower during both light and dark cycles in ahr
-/-
 mice, with 
no difference in heart rate (HR).  Interestingly, endothelial nitric oxide synthase (eNOS) 
protein was upregulated in the aorta, but increased NO bioavailabilty did not mediate the 
resultant hypotension in the ahr
-/-
 mice as demonstrated by the inability of pharmacological 
NOS inhibition to normalized BP (Zhang et al., 2010).  In contrast, inhibition of the renin 
angiotensin system (RAS) by the angiotensin converting enzyme (ACE) inhibitor, 
captopril, produced a less significant decrease in MAP in the ahr
-/-
 mice, suggesting that  
the RAS contributed significantly less to maintaining basal BP in the ahr
-/-
 mice as 
compared to ahr
+/+
 mice.  Nonetheless, indices of RAS activity, including plasma renin 
activity, ACE activity, and plasma Ang II levels were normal, suggesting that hypotension 
in ahr
-/-
 mice may be due to an attenuation of Ang II downstream signaling.  
Additionally, the AHR is activated by shear stress (SS).  SS is the frictional force 
exerted on the vascular endothelium due to blood flow, and is necessary in regulating 
vascular tone and BP.  Laminar SS (10-30 dynes/cm
2
) occurs in linear regions of the 
vasculature and elicits a response in vascular ECs that is predominantly considered to be 
6 
 
anti-atherogenic and anti-proliferative (Traub and Berk, 1998).  The vasoprotective effect 
of laminar SS is mediated, in part, by an upregulation and activation of the endothelial 
NOS (eNOS), and a subsequent increase in NO production.  Under static conditions, 
constitutive expression of AHR and its downstream target gene, CYP1A1, have been 
detected in cultured human ECs, albeit at low levels.  However, upon induction of laminar 
SS (25 dynes/cm
2
), mRNA and protein levels of AHR and CYP1A1 were significantly 
upregulated after 24 h of SS.  Additionally, CYP1A1 activity levels were up seven fold 
after 48 h of laminar SS.  Interestingly, the modest inducible expression was attenuated by 
turbulent SS (Eskin et al., 2004; Conway et al., 2009).  In support of this, Han and 
coworkers demonstrated that laminar fluid SS-induced CYP1A1 activation in vascular 
ECs.  Human umbilical vein endothelial cells subjected to 15 dynes/cm
2 
showed 
upregulation of CYP1A1 protein levels at 2 h, and increased activity at 1 h after SS 
induction (Han et al., 2008).  Interestingly, in bovine aortic endothelial cells subjected to 
SS (15 dyne/cm
2
), eNOS was phosphorylated at serine 1179 (Ser 1179) as early as 2 min, 
while phosphorylation at serine 635 (Ser 635) was detected at 15 min (Boo et al., 2002a; 
Boo et al., 2002b).  The phosphorylation of eNOS at these specific sites increases its 
activity, hence NO bioavailability (Dimmeler et al., 1999; Iwakiri et al., 2002).  Taken 
together, these studies clearly suggest that the activation of AHR and its responsive gene, 
CYP1A1 by SS might contribute to EC regulation, NO production, and overall vascular 
function. 
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Endogenous ligands of the AHR 
The physiological function of AHR as identified from the ahr
-/-
 mice, suggests that 
there is an endogenous mechanism leading to AHR activation, such as the presence of an 
endogenous ligand.  In fact, several endogenous compounds have been shown to 
transactivate the AHR into the nucleus in the absence of xenobiotics, although the 
physiological relevance of these compounds remains unclear.  Some of the compounds 
proposed to activate the AHR include cyclic adenosine monophosphate (cAMP), modified 
low density lipoproteins (LDL), indigo and indirubin, and lipoxinA4.  The second 
messenger cAMP has been shown to transactivate the AHR (Oesch-Bartlomowicz and 
Oesch, 2009).  However, this activation did not result in subsequent dimerization with 
ARNT, a mechanism distinct from that observed with xenobiotic AHR activation.  
Further, modified LDL have also been shown to act as endogenous ligands for the AHR 
(McMillan and Bradfield, 2007a).  Purified LDL from sheared sera was shown to induce 
AHR-signaling by up to six fold compared to static sera.  Induction of AHR signaling was 
also shown with modified LDL after preincubation with sodium hypochloride and in the 
ahr
-/-
 mice, increased accumulation of the AHR-activating LDL was evident.  Indigo and 
indirubin, isolated from human urine and from bovine serum, have also been suggested to 
be endogenous ligands for the AHR.  These compounds bind and activate the AHR 
although activation was about a hundred fold less than dioxin (Adachi et al., 2001; Peter 
Guengerich et al., 2004).  Although the levels of these compounds are low in the 
picomolar range in human urine, it is possible that they may reach physiological nanomolar 
range in certain body compartments required to activate DREs of target genes.  Therefore, 
their physiological relevance cannot be completely disregarded.  Other suggested 
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endogenous ligands include a key metabolite of arachidonic acid, Lipoxin A4 which has 
been demonstrated to induce CYP1A1 and CYP1A2, and in addition, can also serve as 
their substrates (Schaldach et al., 1999).  Chang and colleagues showed using gel shift 
assay that CYP1A1-deficient mouse hepatoma cell lines (c37 cells) contain a 
transcriptionally active AHR-ARNT complex in the absence of an exogenous ligand.  This 
was also detected when wildtype Hepa-1 cells were treated with the CYP1A1 inhibitor, 
ellipticine, suggesting that an unknown CYP1A1 substrate is a possible AHR endogenous 
ligand (Chang and Puga, 1998).  Moreover, derivatives of tryptophan as well as biliverdin 
have been suggested to activate the AHR.  Thus, the translocation of the AHR into the 
nucleus independent of exogenous ligands suggests a biologically relevant role for the 
AHR. 
 
Cytochrome P4501A1 (CYP1A1) 
Regulation and function of CYP1A1 gene  
As mentioned above, CYP1A1 is a xenobiotic metabolic enzyme induced by the 
activation of the AHR, and two regulatory regions of the CYP1A1 gene are responsible 
for its constitutive and inducible expression.  The first region is the DRE which serves as 
the binding site for the AHR/ARNT complex in response to xenobiotics, depicted by the 
sequences 5’-TNGCGTG-3.  In the rat, the DRE has been demonstrated to be positioned 
upstream of the CYP1A1 gene promoter (Fujisawa-Sehara et al., 1987; Neuhold et al., 
1989).  The DRE also serve as a binding site for several transcription factors (Jones and 
Whitlock, 1990).  Nonetheless, in the mouse, six DRE sites have been identified for the 
binding of the AHR/ARNT complex (Denison et al., 1989).  The second regulatory region 
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of the CYP1A1 gene is known as the basal transcription element (BTE) and is involved in 
the constitutive expression of CYP1A1.  Most importantly, these two regulatory regions 
of the human CYP1A1 gene were also shown to be conserved in the mouse (Yanagida et 
al., 1990).  
Chromatin structural analysis of the CYP1A1 gene reveals the presence of a 
nucleosome at the promoter/enhancer region in the absence of an AHR agonist (Morgan 
and Whitlock, 1992).  Activation of the AHR by TCDD led to a conformational change in 
the promoter/enhancer region of the CYP1A1 gene, and the resultant disruption of the 
occupied nucleosome, turning on the CYP1A1 gene.  Additionally, chromatin 
immunoprecipitation experiments have revealed that the CYP1A1 enhancer region is 
hypermethylated in prostate cancer cells, creating an inaccessible chromatin structure, 
thereby preventing xenobiotic responsiveness in these cells (Okino et al., 2006).  
A positive correlation has also been shown between CYP1A1 expression and 
protein kinase C (PKC) signaling.  It was demonstrated that PKC inhibition blocked ligand 
activation of the AHR/ARNT complex and inhibited CYP1A1 induction by TCDD 
(Carrier et al., 1992).  Further analysis revealed that the ligand-dependent nuclear 
translocation of AHR is inhibited by phosphorylation of the amino acid, serine, at position 
12 (Ser12), or Ser36 by PKC.  In contrast, the phosphorylation of the Ser 68 has been 
demonstrated to target the AHR from the nucleus back to the cytoplasm thereby 
attenuating CYP1A1 induction (Ikuta et al., 2004).  Thus, the activity and 
phosphorylation target of PKC directly impacts CYP1A1 expression.  In a 2011 study, it 
was shown that the CYP1A1 promoter harbored a β-catenin binding site.  Signaling 
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through β-catenin contributed to basal expression of CYP1A1 and also, in part, to 
CYP1A1 induction by xenobiotics (Braeuning et al., 2011).  
The best studied function of the CYP1A1 enzyme is the transformation of 
xenobiotics, thereby facilitating their clearance.  The mechanism of action of CYP1A1 has 
been studied extensively, using benzo (a) pyrene (BaP) as substrate.  CYP1A1 metabolizes 
BaP into reactive epoxide intermediates which are then converted to water soluble diol 
epoxides for elimination.  BaP is oxidized by CYP1A1 to BaP-7,8-oxide, which is further  
hydrolyzed by the enzyme epoxide hydrolase to B(a)P-7,8-diol and the two enantiomers 
(+)-BaP-7,8-diol, and (-)-BaP-7,8-diol (Shimada and Fujii-Kuriyama, 2004).  Further 
oxidation of these metabolites produces four diol epoxides that are very reactive (Tang et 
al., 2000).  In rats treated with BaP (10 mg/Kg), CYP1A1 induction was increased after 
24 to 48 h in the lung and liver, and this increased was associated with the presence of 
carcinogenic DNA-adducts (Harrigan et al., 2004; Harrigan et al., 2006).  
 
Expression and localization of CYP1A1 
Constitutive levels of CYP1A1 are non-detectable in the liver.  Nonetheless, one 
primary location where CYP1A1 is constitutively expressed is in vascular endothelial cells 
(ECs).  Several in vitro studies have demonstrated the constitutive expression of 
CYP1A1.  In human umbilical vein endothelial cells (HUVECs), CYP1A1 protein was 
detected by western blot.  Using immunohistochemical staining of mouse aorta, CYP1A1 
was shown to be localized to the endothelial layer, and in addition, immunostaining of 
CYP1A1 protein was also localized specifically to the endothelium of cross-sections of 
human coronary artery (Conway et al., 2009).  In addition to its constitutive expression, 
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CYP1A1 mRNA and protein have also been shown to be induced by physiological level of 
SS in the endothelium (Eskin et al., 2004; Han et al., 2008; Conway et al., 2009).  
Further, several studies have demonstrated the expression of CYP1A1 in the endothelium 
following its induction after treatment with AHR agonists.  Annas and coworkers, 
demonstrated that CYP1A1 was present in blood vessels of the heart, kidneys, and liver as 
detected using substrates for CYP1A1 following induction with AHR agonists, beta-
naphthoflavone (BNF).  Autoradiography was used to localize sites of metabolic 
activation of 
3
H-labeled Trp-P-1 (3-amino-1, 4-dimethyl-5H-pyrido [4, 3-b] indole), a 
heterocyclic amine shown to be metabolized by CYP1A1 (Annas and Brittebo, 1998; 
Annas et al., 2000).  Further evidence comes from detecting the induction of CYP1A1 
after treatment with BNF in the coronary arteries, capillaries, and veins of the heart; portal 
veins of the liver; and afferent and efferent arteries, and glomerular and peritubular 
capillaries in the kidneys (Annas et al., 2000; Granberg et al., 2000).  More evidence has 
been shown with polychlorinated biphenyl (PCB)-mediated induction of CYP1A1 mRNA 
predominantly in vascular endothelium (Farin et al., 1994; Stegeman et al., 1995).  Other 
studies have shown that CYP1A1 mRNA is not constitutively expressed in the mouse 
vascular smooth muscle cells (vsmc), and upon treatment with the AHR agonist, BaP (3 
μmol/L), CYP1A1 protein levels remained uninducible even though mRNA levels were 
upregulated (Kerzee and Ramos, 2001).  Nonetheless, in a 2007 study, Wilson and 
colleagues showed that CYP1A1 mRNA was highly induced in vascular endothelial cells, 
vascular smooth muscle, and nerve cells in the dermis of the bottlenose dolphins, 
suggestive of PCB contamination (Wilson et al., 2007).  In a recent study, C57BL/6 
wildtype mice were treated with the AHR agonist TCDD and CYP1A1 protein induction 
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detected by immunohistochemistry was predominantly localized in the endothelial layer of 
the mesenteric artery and the aorta (Kopf et al., 2010).  Given the importance of the 
endothelium in vascular development and function, it is relevant to consider the role of 
CYP1A1 in the cardiovascular system. 
Additional extrahepatic tissues in which CYP1A1 has been established to be 
present include the intestine, skin and the lung.  In mice treated intraperitoneally with 3-
methylcholanthrene (3MC) (200 mg/kg body weight) for 10 h, CYP1A1 mRNA was 
detected in the villous epithelium and cells around the lamina propria in duodenum, the 
jejunum (Dey et al., 1999), as well as at low levels in the epidermis in normal human 
keratinocytes (Pavek and Dvorak, 2008).  Lastly, CYP1A1 enzyme activity and mRNA 
levels have also been detected in the microsomal fractions of human lung (Smith et al., 
2001; Bernauer et al., 2006). 
 
CYP1A1 polymorphisms and cardiovascular disease  
A plethora of mutations in the CYP1A1 gene have been identified.  The first of 
these polymorphisms denoted CYP1A1*1 occurs at position 3801 whereby thymidine is 
substituted by cytosine.  This polymorphism does not result in differential CYP1A1 
expression.  Another polymorphism involves adenine to guanine substitution at position 
2455 of codon 462 at exon 7.  This polymorphism is known as CYP1A1*2B or Ile462Val 
polymorphism (Hayashi et al., 1991).  Additionally, the msp1 polymorphism whereby 
thymidine is substituted by cytosine at position 3798 (3798T>C), and the Ile462Val 
polymorphisms of CYP1A1 both have been associated with smoking-induced squamous 
cell carcinoma in the lung, and smoking related coronary artery disease (Nakachi et al., 
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1993; Wang et al., 2002).  Recently, another CYP1A1 msp1 gene polymorphism was also 
shown to be associated with greater mortality in patients with acute coronary syndrome 
(ACS) with a history of smoking.  When patients with ACS were genotyped for the 
T6235C polymorphism and the survival rate was stratified by smoking history, the 
CYP1A1 T6235C polymorphism was particularly correlated with mortality of smokers 
whether past or current (Jarvis et al., 2009).  In contrast, the CYP1A1*2C (A4889G)  
polymorphism was shown to be protective against coronary artery disease in the 
Taiwanese population particularly among non-smokers (Yeh et al., 2009).  Lastly, an 
interaction between human polymorphisms of CYP1A1 and AHR was implicated in 
determining blood pressure (BP) among smokers, non-smokers, and ex-smokers (Gambier 
et al., 2006).  Thus, CYP1A1 expression and polymorphisms may play a role in the 
development or pathogenesis of cardiovascular diseases. 
 
Omega-3 Polyunsaturated Fatty Acids (n-3 PUFA)  
n-3 PUFA Biology and the Cardiovascular System 
Epidemiological evidence shows that fish-eating Greenland Inuits exhibit 
significantly lower risk of death from acute myocardial infarction when compared to those 
from the Danish population which consumed less fish.  The Inuit diet provides several 
grams of n-3 PUFAs per day from fish (Blanchet et al., 2000).  More evidence has also 
been seen in the Japanese population with higher fish consumption compared to the United 
States.  A lower rate of acute myocardial infarction and overall death from cardiovascular 
disease is significantly lower in the Japanese population (Menotti et al., 1999).  These 
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observations were some of the first studies to raise the potential of the beneficial and 
cardiovascular protective effects of fish oil. 
Randomized clinical trials in humans have also revealed some benefits of n-3 
PUFA supplementation.  In the Gruppo Italiano per lo Studio della Sopravvivenza 
nell’Infarto Miocardico (GISSI)-Prevenzione (GISSI-Prevenzione) clinical trials, 11,324 
patients surviving recent myocardial infarction were randomly assigned supplements of n-3 
PUFA (1 g/day), vitamin E (300 mg/day), or both for three and a half years.  Treatment 
with n-3 PUFA only, reduces the risk of cardiovascular deaths, myocardial infarction and 
stroke by 15% (1999; Marchioli et al., 2002).  The second large scale clinical trial 
conducted was the Japan EPA lipid intervention study (JELIS).  In 18,645 patients with 
hypercholesterolemia, 1.8 g/day of EPA with statin, or statin only, were assigned for a 
period of 5 years.  In patients with a history of coronary artery disease supplemented with 
EPA, major coronary events and deaths were reduced by 19% (Yokoyama et al., 2007).  
Moreover, in the Diet and Reinfarction Trial (DART), 2,033 Welsh men following 
myocardial infarction were randomly assigned two servings of fish per week for over two 
years.  Cardiovascular deaths were reduced by 29% in patients who consumed fish, 
compared to patients with no fish in their diets (Burr et al., 1989).  Further, in the Study 
on Prevention of Coronary Atherosclerosis by Intervention with Marine Omega-3 fatty 
acids (SCIMO), 223 patients with coronary artery disease were assigned fish oil, at 6 
g/day for 3 months and then 3 g/day for 21 months, or placebo.  The fish oil group had 
significantly more regression of coronary atherosclerotic lesions compared to control 
group (Von Schacky et al., 1999).  Taken together, these clinical trials reveal the 
cardiovascular benefits of n-3 PUFAs.  
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The cardiovascular benefits of n-3 PUFAs are likely mediated through multiple 
mechanisms including anti-hypertensive, anti-arrhythmic, anti-inflammatory, 
vasoprotective, and anti-lipidemic, among others.  In a 1996 study, Chen and colleagues 
showed that the BP-lowering effect of fish oil was independent of thromboxane A2 levels 
in the spontaneously hypertensive rats (Chen et al., 1996).  Further, Engler and colleagues 
followed up with young spontaneously hypertensive rats treated with a DHA-enriched diet 
for 6 weeks.  Systolic BP was reduced by 34 mmHg compared to controls (Engler et al., 
1999).  In addition, in a meta regression analysis of randomized trials in humans, fish oil 
was shown to reduce systolic BP by 2.1 mmHg and diastolic BP by 1.6 mmHg with 
greater effects in hypertensive patients (Geleijnse et al., 2002).  Furthermore, in a 
population-based randomized 10 week long study, 6 g per day of 85 percent EPA and 
DHA were fed to 156 men and women with essential hypertension.  The mean systolic BP 
was reduced by 4.6 mmHg while the diastolic BP by 3 mmHg.  Interestingly, there was no 
change in BP in the control group on corn oil (BÃ¸naa et al., 1990).  Additionally, in a 
meta-analysis of 31 placebo-controlled trials on 1356 subjects, there was a dose response 
effect of n-3 PUFAs on BP with strong association in patients with hypertension and 
atherosclerosis (Morris et al., 1993).  Taken together, these studies provided compelling 
evidence of anti-hypertensive benefits of n-3 PUFAs. 
The majority of studies done so far have been focused on the effects of n-3 PUFAs 
on serum cholesterol levels as well as their role in inflammation and lipoprotein 
metabolism (Bronsgeest-Schoute et al., 1981; Hudert et al., 2006). Nonetheless, few 
studies have investigated the vascular function of n-3 PUFAs.  n-3 fatty acids are essential 
fatty acids for vertebrates because they cannot be synthesized de novo, but rather must be 
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obtained from the diet.  Marine phytoplankton and other aquatic invertebrates can 
synthesize these fatty acids (Yazawa, 1996; Wen and Chen, 2003) and thus, these fatty 
acids biomagnify in fish.  n-3 PUFAs are comprised principally of two key constituents; 
eicosapentaenoic acids (EPA) and docosahexaenoic acids (DHA).  EPA consists of twenty 
carbon atoms with five double bonds (C20:5), whereas DHA is comprised of twenty two 
carbon atoms with six double bonds (C22:6).  In contrast, n-6 fatty acids are more 
saturated (i.e. fewer double bonds) and these include the precursors linoleic acid (LA) and 
arachidonic acid (Fig. 1.2). 
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Figure 1.2. Structure of arachidonic acid, eicosapentaenoic acid (EPA), and 
docosahexaenoic acid (DHA). Arachidonic acid consists of 20 carbon atoms with 4 double 
bonds and the last double bond is sixth from the omega end (n-6), EPA consists of 20 
carbons with 5 double bonds, and the last unsaturated carbon is located third from the 
omega end (n-3).  Docosahexaenoic acid consists of 22 carbons with 6 double bonds, and 
also with the last unsaturated carbon located third from the omega end (n-3).
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           Cytochrome P450s (P450s) and n-3 PUFA metabolism   
P450s display different regioselectivities for n-3 PUFA hydroxylation and 
epoxidation.  Several P450 family members metabolize EPA and DHA as preferred 
substrates.  Recombinant human CYP2J2 has been shown to metabolize EPA and DHA 
into 17,18-epoxyeicosatetraenoic acid (17,18-EEQ), and 19,20- epoxydocosapentaenoic 
acid (19,20-EDP), respectively (Fer et al., 2008).  In addition, all members of the CYP2C 
epoxygenase family, including 2C8, 2C9 and 2C19,  metabolized both DHA and EPA, 
resulting in a large mixture of products including 10,11-, 13,14-, 16,17-, and 19,20-EDP 
from DHA, and 11,12-, 14,15-, and 17,18-EEQ from EPA (Barbosa-Sicard et al., 2005). 
Further, members of the CYP4A family have also been shown to metabolized EPA and 
DHA.  Mouse CYP4a12a metabolizes EPA producing 56% of metabolites as 17,18-EEQ 
(Muller et al., 2007).  Further, human CYP4F2 hydrolyses DHA with higher rates, 
compared to EPA as a substrate (Fer et al., 2008).  Recently, recombinant human 
CYP1A2 and 2D6 were also shown to metabolize EPA and DHA in a stereospecific 
manner to 17(R),18(S)-EEQ, and 19(R),20(S)–EDP, respectively (Lucas et al., 2010). 
Taken together, these results suggest that a large number of P450 families are capable of 
metabolizing n-3 PUFAs. 
 
CYP1A1 and n-3 PUFA metabolism   
CYP1A1 in particular, acts primarily as an epoxygenase toward EPA as substrate 
(Schwarz et al., 2004).  Human CYP1A1 has been shown to epoxidized the 17,18-olefinic 
bond of EPA in a stereospecific manner to form mainly 17(R),18(S)-EEQ, as 70% of its 
metabolites.  CYP1A1 also hydroxylated EPA in a highly regioselective manner to 
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produce 19-OH-epoxypentaenoic acid.  Interestingly, the human CYP1A1 Ile462Val 
polymorphism has been shown to metabolize EPA as substrate with  twice higher rates 
than wildtype CYP1A1 (Schwarz et al., 2005).  This suggests that CYP1A1 metabolism 
of EPA may contribute to differences between individuals in the production of 
physiologically active PUFA metabolites.  CYP1A1 has also been demonstrated to 
metabolize DHA into stereospecific products.  In an in vitro study, recombinant human 
CYP1A1 was shown to convert DHA 100 % to 19(R),20(S)-EDP (Fer et al., 2008). 
Furthermore, the degree of epoxidation for EPA and DHA by CYP1A1 was markedly 
greater compared to arachidonic acid (AA).  CYP1A1 also produced 14,15- 
epoxyeicosatrienoic acid (EET) from AA.  Nonetheless, this accounted for a very small 
percentage of the total epoxides produced. 
 
Cardiovascular function of CYP1A1 metabolites of n-3 PUFAs   
Metabolites of n-3 PUFA metabolism have been shown to exhibit vasoactive 
properties.  In fact, 17,18-EEQ, the product of EPA metabolism by CYP1A1 has been 
reported to induce vasorelaxation in porcine and canine coronary microcirculatory vessels 
(Zhang et al., 2001).  Further, 17,18-EEQ has also been reported to be metabolized to 
novel prostaglandins that are physiologically relevant (Oliw, 1991).  In a recent study, 
17,18-EEQ was shown to relax and hyperpolarize both pulmonary artery and bronchial 
smooth muscle cells in the human lung (Morin et al., 2009).  In the spontaneously 
hypertensive rats, EPA concentration response in aortic rings was shown to elicit 
significantly greater relaxation at all doses compared to the normotensive Wistar-Kyoto 
rats (Engler et al., 1994).  Interesting, in another study, 19,20-EDP, the product of DHA 
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metabolism by CYP1A1 was shown to induce up to 70 % relaxation in porcine coronary 
microvessels, and the mechanism of dilation was shown to be mediated by large 
conductance calcium-activated potassium channels (Ye et al., 2002). Taken together, 
CYP1A1 metabolizes DHA and EPA as substrates into vasoactive metabolites. 
 
Arachidonic acid (AA) as endogenous substrate of CYP1A1 
The cyclooxygenase and lipoxygenase enzymes have been known to metabolize 
AA into 5-, 12-, and 15-hydroxyeicosatetraenoic acid (HETE), prostaglandins, 14,15 
EET, prostacyclins, and thromboxanes (Miller and Vanhoutte, 1985; Churchill et al., 
1989; Escalante et al., 1989; Brock et al., 1999).  Additionally, P450 enzymes, including 
CYP1A1, also use AA as a substrate (Roman, 2002).  CYP1A1 has been shown to act 
mainly as a hydroxylase toward AA metabolism.  Recombinant human CYP1A1 was 
shown to produce 14,15-EET from AA.  Nonetheless, the amount of 14,15 EET produced 
was less than 60% relative to the total epoxides produced from AA, suggesting that AA 
metabolism by CYP1A1 is of less importance compared to EPA and DHA (Fer et al., 
2008; Lucas et al., 2010).  In fact, EETs were shown to be 1000 fold less potent that 
DHA-derived epoxides (Ye et al., 2002).  Regardless, 14,15-EET has been demonstrated 
to relax precontracted coronary microvessels (Campbell et al., 1996), to induce NO-
dependent relaxation in pressurized arterioles in the mouse (Hercule et al., 2009), and to 
dilate the renal microcirculation of rats ex vivo (Imig et al., 1996).  Taken together, these 
studies suggest that CYP1A1-generated EETs have vasodilatory properties, even though 
their potency is less, compared to n-3 PUFA metabolites. 
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Nitric oxide 
Nitric oxide biology, regulation, and the cardiovascular system 
NO is a potent vasodilator that is produced by three unique forms of NOS, 
including eNOS, neuronal NOS (nNOS) and inducible NOS (iNOS).  In the endothelium, 
NO is produced in a reaction catalyzed by eNOS, transforming L-arginine to L-citrulline, 
in the presence of molecular oxygen with several cofactors including NADPH, flavin 
adenine dinucleotide (FAD), flavin mononucleotide (FMN), tetrahydrobiopterin (BH4) and 
Ca
2+
/calmodulin (Ignarro et al., 1987; Palmer et al., 1988).  The primary stimulus that 
increases eNOS activity is a transient increase in intracellular calcium concentration (Busse 
and Mulsch, 1990; Busse and Fleming, 1995).  The availability of both the substrate, L-
arginine, and the co-factor, BH4, also regulates NO production.  BH4, in particular is 
important because in its deficiency, electron transport through eNOS can become 
uncoupled, leading to accumulation of reactive oxygen species as superoxide anions 
(Cosentino et al., 1998; Cherng et al., 2009).  The regulation of NO production has also 
been demonstrated to be affected by the phosphorylation status of eNOS at different 
serine residues, the most important being ser1177 phosphorylation (Fulton et al., 1999).  
Basal NO levels play an important role in regulating vascular tone and BP.  NO 
produced from the endothelium, diffuses across the plasma membrane mediated by 
aquaporin-1, to the underlying vascular smooth muscle cells, and binds to soluble 
guanylate cyclase to produce cyclic guanosine monophosphate (cGMP).  cGMP activates 
protein kinases, resulting in vasodilation by decreasing smooth muscle intracellular Ca
2+ 
(Fig. 1.3).  This NO-mediated vasodilation contributes to basal BP regulation.  In fact, 
mice that overexpress the eNOS enzyme are hypotensive (Ohashi et al., 1998).  
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Conversely, eNOS null mice or mice treated with a NOS antagonist are hypertensive 
(Shesely et al., 1996; Yang et al., 1999).  The dysregulation of NO signaling has been 
implicated in many cardiovascular diseases.  In particular, pathological increases in reactive 
oxygen species have been demonstrated to scavenge NO, leading to loss of NO-mediated 
relaxation as one common contributor to endothelial dysfunction (Fresquet et al., 2006).  
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Figure 1.3. Mechanism of endothelial cell production of NO leading to vascular smooth 
muscle relaxation. Various stimuli, such as acetylcholine, bradykinin, and SS increase 
intracellular calcium levels in endothelial cells which stimulates the production of NO by 
eNOS. NO diffuses to the underlying smooth muscle cell and activates soluble guanylate 
cyclase (sGC) resulting in the accumulation of cGMP. An increase in cGMP activates 
protein kinase G (PKG) and protein kinase A (PKA). Activation of PKA and PKG inhibits 
L-type Ca
2+
 channels, activates sarcoplasmic endoplasmic reticulum Ca
2+
 ATPases 
(SERCA) thereby pumping Ca
2+ 
back into the sarcoplasmic reticulum. This leads to a 
reduction in intracellular calcium in the smooth muscle resulting in vasorelaxation. 
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Nitric oxide and n-3 PUFA crosstalk   
Several studies have investigated potential crosstalk between n-3 PUFAs and NOS 
expression, particularly eNOS.  Treatment of human coronary artery endothelial cells with 
DHA for 7 days tended to increase both total and phospho-eNOS, and upregulated the 
expression of phospho-AKT and HSP90, two proteins involved in the activation of eNOS.  
In addition, nitrate and nitrite (NOx) levels were increased in the media of DHA-treated 
cells, suggesting an increase in NO production (Stebbins et al., 2008).   
In another study, using human cultured umbilical vein endothelial cells, EPA 
stimulated the translocation of eNOS from caveolae to the cytosol, a step required for 
activation.  Interestingly, EPA upregulation of eNOS was not accompanied with a robust 
increase in intracellular calcium (Omura et al., 2001).  Li and colleagues also confirmed 
that EPA stimulated the translocation of eNOS from caveolae (Li et al., 2007a; Li et al., 
2007b).  Additionally, in EA hy 926 endothelial cells, both DHA and EPA significantly 
increased expression of phospho-eNOS, with no change in total eNOS expression 
(Gousset-Dupont et al., 2007). 
Animal studies have also demonstrated a possible crosstalk between eNOS 
expression in caveolae and n-3 PUFAs.  In rats treated with n-3 or n-6 diets, phospholipid 
n-3 fatty acyl content was increased, while caveolin-1 and cholesterol were significantly 
reduced in the colon of n-3 PUFA fed rats compared to n-6.  Moreover, caveolae-resident 
proteins, eNOS and H-Ras were reduced by 45 and 56%, respectively, in rats fed the n-3 
diet, while non-caveolae proteins, K-Ras and clathrin, were not affected (Ma et al., 2004).  
Further evidence also comes from young pigs treated with DHA.  DHA significantly 
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increased BH4 and NADPH levels in the brain, muscle and liver, and increased NOS 
activity by 45-48% in the muscle and brain (Li et al., 2008).  These data further suggest 
that n-3 PUFAs can remodel the microdomain of membranes in vivo, thereby altering the 
localization of proteins, including eNOS.  Taken together, these data suggest that n-3 
PUFAs could lead to increases in NOS activity and potentially in NO bioavailability. 
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Rationale for Research 
Cardiovascular diseases are the leading cause of death in the United States (Roger 
et al., 2011) and  high BP is a major independent risk factor, including stroke, myocardial 
infarction, and coronary artery disease (Stokes et al., 1989).  The AHR has been 
implicated in the regulation of vascular function and BP.  AHR null mice were 
demonstrated to exhibit altitude-induced hypertension with low BP at sea level (Lund et 
al., 2003; Lund et al., 2008).  In addition, cardiac hypertrophy and portosystemic shunting 
were hallmarks of the AHR null mice (Lahvis et al., 2000; Thackaberry et al., 2002).  
Nonetheless, the sustained activation of the AHR results in vascular dysfunction and 
hypertension, and it has been established that this cardiovascular toxicity requires the 
sustained induction of CYP1A1, the AHR downstream target gene (Walker and Catron, 
2000; Kopf et al., 2010).  
However, many questions remain.  The endogenous role of the AHR in the vascular 
endothelium, and its target gene CYP1A1, in the regulation of BP remain to be 
determined.  The AHR and its downstream target gene CYP1A1 have been demonstrated 
to be modestly induced by physiological level of laminar SS in the vascular endothelial 
cells, and in addition, CYP1A1 metabolize n-3 PUFAs as substrate in the production of 
vasodilator metabolites (Schwarz et al., 2004; Schwarz et al., 2005; Han et al., 2008; 
Conway et al., 2009).  These observations strongly suggest that the AHR and its target 
gene, CYP1A1, might be involved in cardiovascular homeostasis.  Thus, the long term 
objective of this study is to elucidate the contribution of the AHR in the vascular 
endothelium and of global CYP1A1 to vascular function and BP regulation in the absence 
of xenobiotics.  
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Central Hypothesis:  The aryl hydrocarbon receptor (AHR) and its downstream target 
gene, cytochrome P4501A1 (CYP1A1), both contribute to normal vascular reactivity of 
blood vessels and to BP regulation. 
Aim 1: Establish the degree to which loss of AHR in ECs contributes to vascular 
reactivity and BP regulation in vivo. 
Rationale: The ahr
-/-
 mice are hypotensive and this is mediated, in part, by a decreased 
contribution of Ang II to maintaining normal basal BP.  However, the specific cell type(s) 
requiring AHR expression for BP regulation is not known, since this phenotype was 
elucidated in the global AHR knockout mouse.  Nonetheless, since it has been shown that 
AHR expression in vascular endothelial cells is required for normal vascular development, 
we hypothesized that loss of AHR in EC would attenuate Ang II-dependent signaling 
resulting in hypotension.  To test this hypothesis we generated EC-specific ahr
-/-
 mice 
(ECahr
-/-
) and investigated the contribution of Ang II to vascular reactivity and BP 
regulation. 
 
Aim 2: Establish the degree to which global deletion of CYP1A1 contributes to vascular 
reactivity in conduit and mesenteric resistance arterioles, and to BP regulation 
Rationale:  CYP1A1 is constitutively expressed in vascular endothelial cells and 
metabolizes n-3 PUFAs, producing vasodilator metabolites that contribute in maintaining 
vascular tone of blood vessels.  However, understanding the contribution of CYP1A1 to 
vasoreactivity and to BP regulation has not been investigated.  Thus, our working 
hypothesis is that global genetic deletion of CYP1A1 will result in reduced vascular 
vasodilatory responses to n-3 PUFAs and increases in BP.  To test this hypothesis we used 
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CYP1A1 KO mice that were generously provided by Dr Daniel Nebert (University of 
Cincinnati), to determine the BP phenotype and n-3 PUFA-mediated vasorelaxation in 
CYP1A1 KO mice. 
 
Aim 3: Determine the degree to which CYP1A1 contributes to changes in vascular 
function and BP as a result of providing an n-3 versus n-6 PUFA-enriched diet. 
Rationale: CYP1A1 stereospecifically metabolizes n-3 PUFAs to potent vasodilatory 
products.  However, numerous studies have demonstrated the involvement of several 
P450s in n-3 PUFA metabolism, in addition to  CYP1A1, including members of the 
CYP2C and CYP4A families (Barbosa-Sicard et al., 2005; Muller et al., 2007).  Thus, it is 
not known if any specific P450 is required to mediate the vascular benefits of n-3 PUFAs.  
In addition, n-3 PUFAs have also been shown to upregulate NOS signaling in animal 
models and in cell culture (Ma et al., 2004; Li et al., 2007a; Li et al., 2007b). Thus, our 
working hypothesis is that an n-3 PUFA-enriched diet, but not an n-6 PUFA-enriched diet, 
will reduce BP in CYP1A1 KO mice via a NOS-dependent mechanism. To test this 
hypothesis we fed CYP1A1 WT and KO mice either a diet enriched in n-3 PUFAs or n-6 
PUFAs, and determine the contribution of CYP1A1 to vascular function and BP 
regulation. 
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II. CHAPTER 2 
Endothelial cell-specific aryl hydrocarbon receptor knockout mice exhibit 
hypotension mediated, in part, by an attenuated angiotensin II responsiveness. 
 
Larry N. Agbor, Khalid M. Elased, and Mary K. Walker. Biochem Pharmacol 5: 514–
523, 2011. 
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A. ABSTRACT 
Hypotension in aryl hydrocarbon receptor knockout mice (ahr
-/-
) is mediated, in part, by a 
reduced contribution of angiotensin (Ang) II to basal blood pressure (BP).  Since AHR is 
highly expressed in endothelial cells (EC), we hypothesized that EC-specific ahr
-/-
 (ECahr
-
/-
) mice would exhibit a similar phenotype.  We generated ECahr
-/-
 mice by crossing AHR 
floxed mice (ahr
fx/fx
) to mice expressing Cre recombinase driven by an EC-specific 
promoter.  BP was assessed by radiotelemetry prior to and following an acute injection of 
Ang II or chronic treatment with an angiotensin converting enzyme inhibitor (ACEi).  
ECahr
-/-
 mice were hypotensive (ECahr
+/+
: 116.1 ± 1.4; ECahr
-/-
: 107.4 ± 2.0 mmHg, 
n=11, p<0.05) and exhibited significantly different responses to Ang II and ACEi.  While 
Ang II increased BP in both genotypes, the increase was sustained in ECahr
+/+
, whereas 
the increase in ECahr
-/-
 mice steadily declined.  Area under the curve analysis showed that 
Ang II-induced increase in diastolic BP (DBP) over 30 min was significantly lower in 
ECahr
-/-
 mice (ECahr
+/+
 1297 ± 223 mmHg/30 min; ECahr
-/-
AUC: 504 ± 138 mmHg/30 
min, p<0.05).  In contrast, while ACEi decreased BP in both genotypes, the subsequent 
rise in DBP after treatment was significantly delayed in the ECahr
-/-
 mice.   ECahr
-/-
 mice 
also exhibited reduced vascular and adipose Ang II type 1 receptor (AT1R) expression, 
and reduced aortic Ang II-dependent vasoconstriction in the presence of vascular adipose.  
Taken together these data suggest that hypotension in ECahr
-/-
 mice results from reduced 
vascular responsiveness to Ang II that is influenced by AT1R expression and adipose. 
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B. INTRODUCTION 
The aryl hydrocarbon receptor (AHR) is a ligand-activated, basic helix-loop-
helix/Per-ARNT-Sim transcription factor involved in the adaptive and toxic responses of 
xenobiotics (McMillan and Bradfield, 2007b).  The most potent ligand for AHR is the 
halogenated aromatic hydrocarbon 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD).  In 
addition to its conventional role in xenobiotic metabolism, recent studies demonstrate a 
novel role for AHR in vascular development and physiological homeostasis in the absence 
of exogenous ligands (Thackaberry et al., 2002; Vasquez et al., 2003).  AHR knockout 
mice (ahr
-/-
) exhibit significant reduction in liver size, which results from the persistence of 
the fetal ductus venosus after birth.  The patency of the ductus venosus greatly reduces the 
portal blood supply, and the failure of this vessel to close is dependent on AHR expression 
solely in vascular endothelial cells (EC) (Lahvis et al., 2000; Walisser et al., 2004; Lahvis 
et al., 2005; Walisser et al., 2005).  Beyond its role in vascular development, the AHR 
also is involved in cardiac development and blood pressure regulation.  AHR deficient 
mice develop cardiac hypertrophy and fibrosis, correlated with an increased size of 
cardiomyocytes (Thackaberry et al., 2002; Vasquez et al., 2003).   
Evidence for the role of AHR in blood pressure regulation has been studied by a 
number of laboratories.  In one study, eight-month-old ahr
-/-
 mice are hypotensive, 
associated with a decreased cardiac output caused by diminished stroke volume (Vasquez 
et al., 2003).  In another study, three-month-old ahr
-/-
 mice are also hypotensive with 
mean arterial pressure (MAP) and systolic (SBP) and diastolic blood pressures (DBP) 
significantly lower during the entire 24 hr light/dark cycle (Zhang et al., 2010).  Although 
both endothelial nitric oxide synthase (eNOS) and its product, nitric oxide (NO), a potent 
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vasodilator, are upregulated in the aorta of ahr
-/-
 mice, the increased NO does not mediate 
the resultant hypotension.  Rather, hypotension in ahr
-/-
 mice is mediated, in part, by a 
decrease in the contribution of the vasoconstrictor, angiotensin (Ang) II, to basal vascular 
tone.  The ahr
-/-
 mice are significantly less responsive to a decrease in blood pressure when 
Ang II formation is inhibited, using the angiotensin converting enzyme (ACE) inhibitor, 
captopril.  These data suggest that Ang II contributes significantly less to maintaining 
basal blood pressure, compared to ahr
+/+
 mice.  Interestingly, however, indices of renin-
angiotensin system (RAS) activity, including plasma renin and ACE activities, and plasma 
Ang II levels, are normal, suggesting that hypotension in ahr
-/-
 mice may be due to an 
attenuation of Ang II signaling (Zhang et al., 2010).  
In addition to the classic circulating components of the RAS, localized tissue RAS 
also has been identified in numerous tissues, including the heart, brain, blood vessels, and 
adipose (Stoll et al., 1995; Vaughan et al., 1995).  Angiotensinogen, the precursor of Ang 
II, is secreted by white adipose tissue and all the components of the RAS are localized in 
rat and human adipose (Engeli et al., 1999; Engeli et al., 2000; Giacchetti et al., 2000).  
The perivascular adipose tissue (PVAT) is interspersed with vasa vasorum and transmits 
secreted factors that act in a paracrine manner on the underlying blood vessels to modulate 
vascular tone and contribute to blood pressure regulation.  These secreted factors include 
vasodilators, such as adipocyte-derived relaxing factor, Ang1-7, hydrogen peroxide, and 
others (Lohn et al., 2002; Verlohren et al., 2004; Gao et al., 2007), as well as 
vasoconstrictors, including Ang II and superoxide anion (Massiera, 2001; Gao et al., 
2006).  Therefore, adipose is a major vasoregulator of blood pressure, in part, by 
contributing to overall RAS activity in the blood vessels. 
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Since AHR is highly expressed in the endothelium, and endothelial AHR is 
required for normal vascular development, it seemed logical to investigate the contribution 
of endothelial AHR to blood pressure regulation.  To this end, we generated ECahr
-/-
 mice 
using Cre-lox recombination to elucidate the mechanism by which AHR in the 
endothelium modulates blood pressure.  We hypothesized that loss of AHR in EC will 
attenuate Ang II-dependent signaling resulting in hypotension. 
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C.        METHODS 
Mouse models  
Mice expressing the ahr floxed allele (ahr
fx/fx
) were crossed to mice expressing a Cre 
transgene driven by the Tie2 kinase promoter enhancer (Tek) (CreTek, strain name: 
B6.Cg-Tg(Tek-cre)12FlvJ; (The Jackson Laboratory, Bar Harbor, ME) (Postic et al., 
1999; Koni et al., 2001).  Mice homozygous for the floxed allele and hemizygous for the 
Cre transgene (ahr
fx/fx
Cre
Tek
) were obtained by crossing male ahr
fx/+
Cre
Tek
 mice to female 
ahr
fx/fx
 mice.  Littermates that were Cre negative were used as genetic controls.  Because 
Cre
Tek
 activity results in the deletion of floxed targets in the female germ line, male mice 
expressing the ahr
fx/fx
 allele and the Cre
Tek
 transgene were used to transmit Cre
Tek
 to the 
offspring.  Only male mice were used in subsequent experiments.  All animal protocols 
were approved by the University of New Mexico Animal Care and Use Committee and 
the investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the U. S. National Institutes of Health (NIH Publication No.  85-23, revised 
1996).     
 
Assessment of ahr excision 
PCR analysis was used to genotype for the Cre transgene using DNA isolated from 
tail snips.  The reaction contained 0.6 µM of each primer (Table 2.1) and 0.05 U/µl Tag 
Polymerase (Promega, Madison, WI, USA), and 1X buffer (Epicentre Biotechnologies, 
Madison, WI, USA).  PCR was carried out for 39 cycles (94°C/1 min; 55°C/1 min; 72°C/2 
mins).  A 450-bp band confirmed the presence of the Cre transgene.  Analysis of ahr
fx/fx
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excision was carried out by multiplex PCR using 1 µM of two forward primers and one 
reverse primer (Table 2.1S, supplemental data), and  0.025 U/µl Taq Polymerase 
(Promega), 1X PE Buffer II (Applied Biosystems, Foster City, CA,USA), 2 mM MgCl2, 
and 0.2 mM dNTPs.  PCR was carried out for 29 cycles (95°C/30 s; 60°C/30 s; 72°C/30 
s).  
 
Assessment of endothelial AHR expression 
Aortas were fixed in 10% neutral-buffered formalin and embedded in paraffin.  
Five micron sections were immersed in 1X Tris-EDTA buffer at 95
o
C for 15 min for 
antigen retrieval.  Sections were then treated with 3% hydrogen peroxide to block 
endogenous peroxidase activity, followed by blocking with 10% goat serum.  Mouse 
monoclonal anti-AHR antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was 
applied (1:200) overnight at 4
o
C.  After washing, a secondary antibody, goat anti-mouse 
conjugated to horseradish peroxidase (SouthernBiotech, Birmingham, AL, USA), was 
applied for 1 h at room temperature (1:200).  Slides were washed, stained with 3, 3’-
diaminobenzidine tetrahydrochloride solution (Vector Laboratories, Burlingame, CA, 
USA) for 5 min, and counterstained with methyl green.  Sections treated only with second 
antibody were used as negative controls.  
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 In vivo analysis of blood pressure 
Arterial blood pressure and heart rate were measured using radiotelemetry (Data 
Sciences International, St. Paul, MN, USA) as described (Lund et al., 2008), using PA-
C10 telemeters.  Mice were allowed to recover from surgery for 7 d prior to data 
collection.  Basal blood pressure, including systolic, diastolic, mean and pulse arterial 
blood pressure, and heart rate were collected for 7 d before drug treatments began.  Blood 
pressure was recorded for 10 s every 15 min during baseline measurements and chronic 
drug treatment, or for 10 s every 1 min for 30 min starting 5 min after prazosin, 
hexamethonium, or Ang II injection.  
 
Drug treatments 
To determine the effects of Ang II on blood pressure, mice were treated with 4 
mg/kg captopril (angiotensin converting enzyme inhibitor, ACEi) in the drinking water for 
5 d followed by a 4 d washout (Lund et al., 2003).  To further elucidate the contribution 
of Ang II to blood pressure, mice were subsequently challenged with an i.p. injection of 
Ang II (30 µg/kg).  Prazosin (1 mg/kg) or hexamethonium (30 mg/kg) was injected i.p. 
into conscious animals to assess acute responses in blood pressure and heart rate (Chen et 
al., 2005), while N
ω
-nitro-L-arginine (LNNA) was administered in the drinking water (250 
mg/L) to assess chronic changes in blood pressure for 2 wk followed by a 1 wk washout 
(Duling et al., 2006).  In all experiments blood pressure was monitored prior to, during 
and after drug treatments.  All drugs were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). 
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Urine collection and analysis 
ECahr
-/-
 and ECahr
+/+
 mice were placed into metabolic mouse cages, one animal 
per cage, with access to food and water ad libitum.  Mice were acclimated to the cage for 
24 h and urine generated during this period was discarded.  Then, 24 h urine samples were 
collected twice in the subsequent 48 h and pooled.  Urine was analyzed for osmolality 
using the Vapro™ Vapor Pressure Osmometer, model 5520 (Wescor, Inc Biomedical 
Division, Logan, UT, USA).  Urinary nitrate/nitrite levels (NOx) were measured using the 
Griess colorimetric assay (Cayman Chemical, MI, USA). 
 
Analysis of plasma ACE, renin activity, and salt balance 
Plasma renin activity (PRA) was determined using a commercial kit (GammaCoat
® 
Plasma Renin Activity 
125
I Kit; DiaSorin, Stillwater, MN) (Senador et al., 2009).  The 
PRA assay is a two-step process, where first angiotensin I is generated and second 
angiotensin I is detected by a radioimmunoassay.  PRA is expressed as ng/ml/hr of 
generated angiotensin I.  Plasma ACE activity was determined using a commercial kit 
(Alpco Diagnostics, Salem, NH, USA).  Plasma samples were incubated with a synthetic 
ACE substrate, 
3
H-hippuryl-glycyl-glycine, and the product, 
3
H- hippuric acid, was 
extracted and measured in a beta counter.  ACE activity was expressed as Units/Liter.  
One unit of ACE activity was defined as the amount of enzyme required to release 1 µmol 
of hippuric acid per minute per liter of plasma at 37° C.  
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mRNA analysis of renin, angiotensinogen, and AT1R from adipose and aorta 
Total RNA was isolated from perirenal visceral white adipose, aortic PVAT, and 
aortas cleaned of adipose tissue, using Trizol reagent (Invitrogen, Carlsbad, CA, USA). 
cDNA was synthesized using iScript Select cDNA Synthesis Kit (Bio-Rad Laboratories, 
Hercules, CA) with the supplied random primers and 250 ng RNA. PCR amplification was 
performed using an iCycler (Bio-Rad Laboratories) with a reaction mixture comprised of 
iQ SYBR Green Supermix (Bio-Rad Laboratories) with 500 μM of each forward and 
reverse primer (Table 2.1S, supplemental data).  Cycle threshold data for both the target 
gene of interest and control normalization gene, DNA Polymerase II (POL2) for adipose 
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for aorta, were used to 
calculate mean normalized expression as previously described (Simon, 2003). 
 
Aortic AT1R protein analysis  
Abdominal aortas, free of PVAT were homogenized in RIPA buffer (Santa Cruz 
Biotechnology), the homogenate frozen at -80 °C, thawed, sonicated and centrifuged at 
15,000 x g 4 °C for 10 min.  Protein concentration in the supernatant was measured using 
micro BCA protein assay kit (Thermo Scientific, Rockford, IL, USA).  A 30 µg aliquot of 
protein was analyzed on a 10 % Tris-HCL polyacrylamide gel for AT1R protein, using 
rabbit anti-AT1R antibody (Santa Cruz Biotechnology), and GAPDH (Millipore, Billerica, 
MA, USA) as a normalization control. 
 
Ex vivo analysis of abdominal aortic reactivity 
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The abdominal aorta was removed, placed in ice-cold physiological saline (PSS) 
containing 130 nM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 15 mM 
NaHCO3, 5.5 mM glucose, 26 µM CaNa2EDTA, 1.8 mM CaCl2, pH 7.4.  The abdominal 
aorta in presence or absence of  PVAT was cut into 2 mm segments and individual rings 
were suspended in an organ bath containing PSS at 37°C bubbled with 21% O2, 6% CO2, 
balanced N2.  The rings were attached to a force transducer (Grass Technologies, West 
Warwick, RI, USA) with steel hangers and resting tension was increased step wise to 1.5 
g over 30 min.  After equilibration, rings were treated with KCl (80 mM) for 5 min.  
Thereafter, rings were treated to 100 nM and 500 nM Ang II.  After a final washout, 
contraction with 10 µM phenylephrine (PE) for 5 min was followed by relaxation with 10 
µM acetylcholine (ACh) to determine the viability of the rings.  Rings with dilation less 
than 50% were discarded.  All chemicals were purchased from Sigma-Aldrich.  
 
Statistical analysis 
Differences among genotypes were analyzed by student’s t-test.  The treatment-
related changes in blood pressure between genotypes were analyzed by repeated measures, 
two-way analysis of variance with post hoc Holm-Sidak comparisons; *P < 0.05 was 
considered statistically significant in all cases.  
40 
 
D. RESULTS 
ahr excision as determined by PCR and endothelial AHR deletion as determined by 
immunohistochemistry 
PCR amplification of the ahr
fx/fx
-unexcised allele results in a 140-bp band, while 
amplification across the ahr
fx/fx
-excised allele amplifies a 180-bp band.  PCR amplification 
of the WT allele, when present, generates a 106-bp band (Walisser et al., 2005).  Our 
results demonstrated the successful excision of the ahr
fx/fx
 allele in organs that contain EC 
and specifically in conduit and resistance blood vessels, including the aorta and mesenteric 
arteries, respectively (Fig. 2.1A).  Further, immunohistochemistry confirmed the deletion 
of AHR protein from the endothelium of the aorta of ECahr
-/-
 mice, compared to ECahr
+/+
 
mice (Fig. 2.1B).   
 
Basal blood pressure, activity, and organ weights 
Blood pressure of ECahr
-/-
 and ECahr
+/+
 littermates was measured by 
radiotelemetry.  The ECahr
-/-
 mice exhibited significantly lower SBP and DBP, compared 
to ECahr
+/+
 mice (Fig.  2.2A).  Pulse pressure (data not shown) and heart rate were 
normal (Fig. 2.2B).  The decrease in blood pressure in ECahr
-/-
 mice was evident 
throughout the entire 24 h light/dark cycle, although the circadian pattern of MAP 
exhibited a normal increase during the night wakeful period (Fig. 2.2C).  The level of 
activity was comparable between ECahr
-/-
 and ECahr
+/+
 mice during the 24 h light/dark 
cycle (Fig.  2.2D).  Finally, ECahr
-/-
 mice exhibited a decreased liver weight and cardiac 
hypertrophy accompanied by renal enlargement (Table 2.1), but did not exhibit any 
changes in weight of adipose tissue (Table 2.2S, supplemental data).  
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Figure 2.1. Cre
Tek
-mediated excision of the ahr floxed allele (ahr
fx/fx
).  (A) Excision by 
Cre
Tek
 was determined by genotyping for both the unexcised (140 bp) and excised (180 
bp) alleles of ahr
fx/fx 
in genomic DNA isolated from liver, kidney, heart, aorta and 
mesenteric arterioles obtained from ahr
fx/fx
Cre
-
 (ECahr
+/+
) and ahr
fx/fx
Cre
+
 (ECahr
-/-
) mice.  
(B) Representative sections of aorta from ECahr
-/-
 and ECahr
+/+
 mice stained with primary 
AHR antibody.  Positive horseradish peroxidase activity (arrows) can be seen in the 
endothelium of ECahr
+/+
, but absent in the ECahr
-/-
 mice. 
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Figure 2.2. Loss of ahr alleles in endothelial cells (EC) decreases systolic and diastolic 
blood pressure.  (A) Systolic and diastolic blood pressure, (B) heart rate, (C) hourly mean 
arterial pressure (MAP) over a 24 hr period (light and dark cycle), and  (D) activity of 
ECahr
+/+
 and ECahr
-/-
 mice, as measured by radiotelemetry (n=12/genotype).  Data 
represent mean ± SEM and were analyzed by Student’s t-test; *p < 0.05, compared to 
ECahr
+/+
 (A and B) or by two-way, repeated measures ANOVA, using post hoc Holm-
Sidak comparisons; *p < 0.05, compared to ECahr
+/+
 mice (C and D).  
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Table 2.1. Body and organ weights of 4-
month-old male ECahr
+/+
 and ECahr
-/-
 mice.   
Weight ECahr
+/+
 
(n=10) 
ECahr
-/-
 
(n=14) 
Body (g) 
 
28.8 ± 0.8 28.7 ± 0.8 
Heart (mg) 119 ± 4 
(0. 412 ± 0. 
104)
†
 
130 ± 4 
(0. 455 ± 0. 
137)* 
LV+S (mg) 91.1 ± 3 
(0. 320 ± 0. 099) 
102 ± 3* 
(0. 358 ± 0. 
087)* 
Kidney (mg) 356 ± 17 
(0. 616 ± 0. 171) 
398 ± 14 
(0. 694 ± 0. 
162)* 
Liver (mg) 
 
1412 ± 52 
(0. 049 ± 0. 180) 
1110 ± 57* 
(0. 039 ±0. 168)* 
Values are expressed as mean ± SEM 
*P < 0.05 
†
 (Organ/body weight ratio x 100) 
Legend: LV+S, Left ventricle + Septum.  
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Inhibition of NOS on blood pressure 
To determine the potential contribution of NOS and NO to hypotension in ECahr
-/- 
mice, we treated ECahr
+/+
 and  ECahr
-/-
 mice chronically with the NOS inhibitor, LNNA 
(250 mg/L) in drinking water for 2 wk and assessed changes in blood pressure by 
radiotelemetry.  There was an increase in MAP during LNNA treatment in both ECahr
-/-
 
and ECahr
+/+
 mice, and the relative change in MAP was similar between the two 
genotypes (Fig. 2.3A and B).  After treatment ended, MAP returned to baseline in both 
genotypes.  To further determine if vascular eNOS or systemic NO levels were altered, we 
measured aortic eNOS mRNA and protein, and urinary NOx.  Aortic eNOS expression 
and urinary NOx levels did not different between ECahr
-/-
 and ECahr
+/+
 mice (Fig. 2.1S, 
supplemental data).   
 
Sympathetic nervous system activity and intrinsic heart rate 
 
             To determine if a reduction in the sympathetic contribution to vascular tone or a 
lower intrinsic heart rate drives the hypotension in the ECahr
-/-
 mice, we assessed changes 
in MAP and heart rate in ECahr
-/-
 and ECahr
+/+
 mice, following an acute exposure to 
prazosin, an α1 adrenoceptor antagonist, or to hexamethonium, a ganglionic blocker.  We 
found that MAP decreased significantly more in the ECahr
-/-
 mice after prazosin 
(ECahr
+/+
; -5.3 ± 1.7 mmHg; ECahr
-/-
:-11.7 ± 2.3 mmHg, n=4/genotype, p<0.05) and 
hexamethonium treatment (ECahr
+/+
; -18.2 ± 1.8 mmHg; ECahr
-/-
:-25.8 ± 1.5 mmHg, 
n=4/genotype, p<0.05), compared to ECahr
+/+
 mice, suggesting that sympathetic 
contribution to vascular tone is increased (Fig. 2.2S, supplemental data).  However, the 
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intrinsic heart rate observed following hexamethonium treatment was similar between 
genotypes. 
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Figure 2.3. ECahr
-/-
 mice exhibit normal responses to NOS inhibition by LNNA in vivo.  
(A) Change in MAP after treatment with 250 mg/L LNNA in drinking water of male 
ECahr
-/-
 and ECahr
+/+
 mice.  (B) Percent change in MAP after treatment with 250 mg/L 
LNNA.  Data represent mean ± SEM and were analyzed by two-way, repeated measures 
ANOVA, using post hoc Holm-Sidak comparisons; *p < 0.05, compared to ECahr
+/+
 (A), 
and by Student’s t-test (B) (n=8/genotype for all experiments).   
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Functional assessment of Ang II responsiveness in vivo 
To determine if hypotension in the ECahr
-/-
 mice was due to reduced 
responsiveness to Ang II in vivo, we challenged ECahr
-/-
 and ECahr
+/+
 mice with a bolus 
dose of Ang II (30 µg/kg) and recorded the blood pressure response starting 5 min after 
injection.  An immediate, robust response to Ang II was demonstrated by a comparable 
increase in MAP in both genotypes during the first 2 min (ECahr
-/-
: 150 ± 2 mmHg; 
ECahr
+/+
 140 ± 10 mmHg) (Fig. 2.4).  However, the subsequent change in blood pressure 
after the first 5 min differed considerably between genotypes.  MAP in ECahr
+/+
 mice 
remained highly elevated (150 ± 8 mmHg at 5 min) with only a very modest decrease after 
30 min (137 ± 3 mmHg).  In contrast, the MAP in ECahr
-/-
 mice exhibited a steady decline 
(138 ± 2 mmHg at 5 min) with significantly lower MAP values being evident as early as 9 
min (136 ± 2 mmHg) and dropping further by 30 min (122 ± 4 mmHg) (Fig.  2.4A).  
Interestingly, the SBP response was similar between ECahr
-/-
 and ECahr
+/+
 mice, although 
SBP did decrease slightly faster in the ECahr
-/-
 mice reaching significantly lower values by 
20 min (Fig. 2.4B).  In contrast, the DBP response was significantly diminished in ECahr
-/-
 
mice across all time points beginning as early as 3 min (Fig. 2.4C).  Area under the curve 
analysis following Ang II injection showed that the increase in DBP was significantly 
attenuated in ECahr
-/-
 mice (ECahr
-/-
AUC: 504 ± 138 mmHg/30 min; ECahr
+/+
AUC: 1297 ± 
223 mmHg/30 min, p<0.05), while the increase in SBP was not different between 
genotypes (ECahr
-/-
AUC: 702 ± 70 mmHg/30 min; ECahr
+/+
AUC: 1106 ± 150 mmHg/30 min, 
(p>0.05)( Fig. 2.4D).  
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Figure 2.4. Loss of ahr in endothelium attenuates RAS responsiveness in vivo.  (A) MAP 
response, (B) change in systolic, (C) change in diastolic blood pressure, and (D) area 
under curve analysis, for 30 min following i.p. injection of Ang II (30 µg/kg).  Blood 
pressure was recorded starting after 5 mins of Ang II administration to exclude handling 
as a confounding factor.  Data represent mean ± SEM and were analyzed by two-way, 
repeated measures ANOVA, using post hoc Holm-Sidak comparisons; *p < 0.05 
compared to ECahr
+/+ 
(Fig. A, B, and C).  Data in panel (D) were analyzed by student t-
test *p < 0.05 compared to ECahr
+/+
 (n=4/genotype). 
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 Inhibition of RAS on blood pressure 
To further elucidate the contribution of the RAS to the hypotension in ECahr
-/-
 
mice, we investigated the responsiveness of ECahr
-/-
 and ECahr
+/+
 mice to an ACEi.  We 
found that captopril significantly decreased MAP, SBP and DBP in mice of both 
genotypes after 5 d of treatment.  While the decrease tended to be greater in ECahr
+/+
 
mice during the first days of treatment, it was not statistically different than the drop seen 
in ECahr
-/-
 mice (Fig. 2.5A, B and C).  Interestingly, during the 4 days of washout after 
drug treatment stopped, MAP and DBP remained significantly lower and did not return to 
baseline in ECahr
-/-
 mice, compared to ECahr
+/+
 mice (Fig. 2.5A, C and D).  To determine 
if any components of the systemic RAS or indices of RAS activity, such as salt and water 
balance were altered, we evaluated PRA, ACE activity, plasma electrolytes and urine 
osmolality.  We found that all, except plasma K, were similar between ECahr
-/-
 and 
ECahr
+/+
 mice, and although plasma K was slightly reduced in ECahr
-/-
 mice it was still 
within normal physiological limits (4.0 - 7.0 mM) (Table 2.2). 
 
mRNA analysis of RAS components from adipose and aorta  
 To determine if tissue RAS components were altered in their expression, we 
measured mRNA of renin, angiotensinogen (Agt) and AT1R in visceral white adipose, 
aortic PVAT, and in aortas cleaned of adipose tissue.  We found that Agt mRNA was 
significantly increased in aortic PVAT in ECahr
-/-
 mice, but not altered in either visceral 
white adipose or the aorta proper, compared to  ECahr
+/+
 mice (Fig. 2.6A).  In addition, 
both renin and AT1R mRNA was significantly reduced in visceral adipose from ECahr
-/-
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mice, compared to ECahr
+/+
 mice, but not altered in aortic PVAT or the aorta (Fig. 2.6B 
and C). 
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Figure 2.5. Loss of ahr in endothelium attenuates the contribution of Ang II to basal 
blood pressure.  (A) MAP response, (B) change in diastolic, and (C) change in systolic 
blood pressure, following treatment with 4 mg/kg ACEi, captopril, in drinking water for 5 
d, followed by a 4 d washout.  (D) Area under the curve analysis of systolic and diastolic 
blood pressure response during washout.  Data represent mean ± SEM and were analyzed 
by repeated measures two-way ANOVA, using post hoc Holm-Sidak comparisons; *p < 
0.05, compared to ECahr
+/+
 (Fig. A, B and C).  Data in panel (D) were analyzed by 
student’s t-test *p < 0.05, compared to ECahr+/+ (n=4/genotype).  
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Table 2.2.  Indices of the renin-angiotensin system (RAS) in ECahr
+/+
 and ECahr
-/-
 mice.  
Parameter ECahr
+/+
 (n) ECahr
-/-
 (n) 
PRA (ng Ang I/ml/hr) 3.9 ± 0.2 (10) 3.7 ± 0.2 (10) 
Plasma ACE (units/L) 196 ± 7 (10) 189 ± 9 (10) 
Hematocrit (%) 46. 8 ± 0.6 (9) 44. 9 ± 1.0 (8) 
Plasma Na (mM) 148. 4± 0.8 (9) 146. 2 ± 0.9 (8) 
Plasma K (mM) 6. 8 ± 0.2 (9) 5. 8 ± 0. 2 (8)* 
Plasma Cl (mM) 118. 2 ± 1.2 (9) 115. 4 ± 0.9 (8) 
Urine Osmolality (mmol/Kg) 3566.9 ± 216 (9) 3952.1 ± 260 (14) 
Values are expressed as mean ± SEM 
*p < 0.05; n, sample size.  
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Figure 2.6. Loss of ahr in endothelium alters mRNA expression of RAS components in 
adipose.  mRNA quantification of (A) Agt, (B) renin, and (C) AT1R from visceral white 
adipose, aortic PVAT, and aorta free of PVAT.  Data represent mean ± SEM and were 
analyzed by Student’s t-test; *P < 0.05, compared to ECahr+/+. 
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AT1R protein expression and aortic reactivity to Ang II 
To determine if the decreased responsiveness to Ang II could result from 
decreased protein expression of the AT1R ECahr
-/-
 mice, we measured AT1R protein 
expression in aortas cleaned of adipose.  We found that AT1R protein expression in the 
aorta free of adipose was significantly lower in the ECahr
-/-
, compared to ECahr
+/+
 mice 
(Fig. 2.7A and B).  To further determine if vascular reactivity to Ang II was decreased in 
ECahr
-/-
 mice, and if this was influenced by the presence of PVAT, we examined ex vivo 
abdominal aortic reactivity to two different doses of Ang II in the presence and absence of 
aortic PVAT.  We found that responsiveness of the abdominal aorta to Ang II was 
completely normal in ECahr
-/- 
mice in the absence of PVAT (Fig. 2.8A).  However, we 
found that the responsiveness of the abdominal aorta to Ang II was significantly 
attenuated in ECahr
-/-
 mice in the presence of PVAT (ECahr
+/+
; 0.2 ± 0.04 ; ECahr
-/-
: 0.1 
± 0.01, n=11/genotype, p<0.05) (Fig. 2.8B).    
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Figure 2.7. Loss of ahr in endothelium diminishes AT1R expression in aorta.  (A)  
Representative western blot of abdominal aortic AT1R protein expression.  (B) 
Quantification of AT1R protein expression relative to GAPDH.  Data represent mean ± 
SEM and were analyzed by Student’s t-test; *P < 0.05, compared to ECahr+/+. 
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Figure 2.8. Loss of ahr in endothelium reduces abdominal aortic reactivity to Ang II in 
the presence of perivascular adipose tissue (PVAT).  (A) Ang II-induced contraction (% 
KCl) in absence of PVAT.  (B) Ang II-induced contraction (% KCl) in the presence of 
PVAT.  (ECahr
-/-
 n=12; and ECahr
+/+
 n=11).  Data represent the mean ± SEM and were 
analyzed by Student’s t-test; *P < 0.05, compared to ECahr+/+. 
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E.        DISCUSSION 
 
 The findings from our study show for the first time that AHR in the endothelium 
is critically involved in blood pressure regulation and is required to maintain normal basal 
levels of blood pressure.  Notably, ECahr
-/-
 mice are significantly hypotensive and this 
phenotype is associated with alter gene expression of tissue RAS components as well as 
decreased protein expression of vascular AT1R.  Further, the hypotension is mediated, in 
part, by a reduction in vasoconstrictive responsiveness to Ang II, measured both in vivo 
and ex vivo.  The blood pressure phenotype in ECahr
-/-
 mice is nearly identical to that 
observed in the global AHR knockout mice, demonstrating that endothelial-expressed 
AHR is a critical regulator of vascular control of blood pressure and this function cannot 
be compensated by the normal expression of AHR in other tissues or cell types.        
Hypotension can have many physiological etiologies, such as decreases in the 
contribution of the sympathetic nervous system to vasoconstriction or increases in 
vascular eNOS expression and NO production.  For example, genetic deletion of α1 
adrenergic receptors or transgenetic overexpression of vascular eNOS both produces 
hypotension (Ohashi et al., 1998; van Haperen et al., 2002; Sanbe et al., 2007).  
However, our data rule out these two possible mechanisms in contributing to the 
hypotension observed in ECahr
-/-
 mice.  Treatment of ECahr
-/-
 mice with the α1 
adrenoceptor blocker, prazosin, or the ganglionic blocker, hexamethonium, significantly 
reduce blood pressure in ECahr
-/-
 mice, suggesting that sympathetic nervous system 
control of blood pressure is actually enhanced in ECahr
-/-
 mice, rather than reduced.  
Additionally, neither eNOS expression nor NOx levels are increased in ECahr
-/-
 mice and 
chronic NOS inhibition increases blood pressure to the same degree in both genotypes.  
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Taken together these data suggest that increased NO is not responsible for the 
hypotension in ECahr
-/-
 mice.  This observation is consistent with that observed for the 
global AHR knockout mice (Zhang et al., 2010). 
              Another mechanism that may mediate hypotension in ECahr
-/-
 mice is a reduction 
in RAS signaling.  Several studies have demonstrated the requirement for the RAS in 
maintaining basal blood pressure within a normal range.  Mice that lack angiotensinogen, 
ACE, or AT1R, have all been shown to be hypotensive (Kim et al., 1995; Esther et al., 
1996; Tsuchida et al., 1998), and our data clearly demonstrate a decrease of Ang II 
signaling both in vivo and ex vivo.  In vivo exposure of ECahr
-/-
 and ECahr
+/+
 mice to an 
acute dose of Ang II produces an immediate rise in blood pressure in both genotypes; 
however, this increase is not sustained in the ECahr
-/-
 mice.  Further, the steady decline in 
DBP in ECahr
-/-
 mice after acute Ang II injection suggests a significant reduction in the 
duration of the vasoconstrictor response.  In addition, chronic exposure of ECahr
-/-
 and 
ECahr
+/+
 mice to an ACEi reduces blood pressure in both genotypes; however, the 
subsequent increase in DBP after drug treatment is stopped is significantly attenuated in 
ECahr
-/-
 mice, further suggesting a decrease in response to Ang II-mediated 
vasoconstriction.  These in vivo data are further supported by ex vivo vasoreactivity data 
that show abdominal aortas from ECahr
-/-
 mice are significantly less responsive to Ang II-
mediated constriction in the presence of PVAT.  It is notable that although Ang II 
responsiveness is reduced, other indices of RAS activity are normal, including PRA and 
ACE activity, renin, angiotensinogen, and plasma Ang II.  Taken together these data 
suggest that downstream signaling of Ang II is reduced. 
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One mechanism by which Ang II-mediated vasoconstriction could be reduced is by 
a reduction in receptor expression.  Both pharmacological blockade of AT1R and genetic 
deletion of AT1R reduce blood pressure (Kim et al., 1995; Iyer et al., 1996; Lu et al., 
1997).  Our data show that loss of endothelial AHR significantly reduces white adipose 
expression of AT1R mRNA as well as aortic expression of AT1R protein.  The 
mechanism by which AHR deficiency reduces AT1R expression is not known.  The AHR 
regulates gene expression via binding to dioxin response elements (DRE) containing the 
core recognition motif 5’-GCGTG-3’(Swanson et al., 1995).  Putative DREs are located 
in the promoter sequence of both the mouse AT1a and AT1b receptors, supporting the 
plausibility that expression of the mouse AT1R could be directly regulated by AHR.  This 
is further supported by the fact that activation of the AHR by exogenous ligands sensitizes 
mice to Ang II-mediated hypertension (Aragon et al., 2008), and induces AT1R mRNA 
expression in mesenteric arteries (unpublished data).  Further, physiological shear stress 
has been shown to activate the AHR (Eskin et al., 2004; Han et al., 2008; Conway et al., 
2009), and to increase AT1R expression (Lindstedt et al., 2009), providing indirect 
evidence that AHR may contribute to the regulation of AT1R expression. Additionally, the 
AHR interacts with several other transcription factors including E2F1, TFIIE, TFIIB, as 
well as coactivators like CREB-binding protein, CBP/p300 and nuclear receptor-
interacting protein 1 (RIP140) (Swanson and Yang, 1998; Hankinson, 2005) and thus 
alteration in AT1R expression could result from crosstalk with other signaling pathways.     
Despite the observed reduction in vascular AT1R expression, this is unlikely to be 
the sole explanation for the hypotensive phenotype observed in ECahr
-/-
 mice, since 
vasoreactivity to Ang II ex vivo is not significantly attenuated in the absence of PVAT.  
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Rather, a significant decrease in vasoconstriction to Ang II is only observed in ECahr
-/-
 
mice in the presence of PVAT.  It is possible that loss of AHR from the endothelium might 
alter the paracrine signaling between that occurs between the microcirculation and the 
adipose, including PVAT.  Both renin and AT1R mRNA were significantly decreased in 
expression in visceral white adipose, which might contribute to a reduction in Ang II 
release from the adipose and a shift in the balance between vasoconstrictors and 
vasodilators released from adipose.  It has been shown that stimulation of adipose AT1R 
by Ang II acts in a feedforward mechanism to increase adipocyte release of Ang II 
(Takemori et al., 2007).  It is also possible the loss of AHR from the endothelium 
increases vasodilators released from adipose.  These dilators could include the newly 
discovered hydrogen sulphide gas (H2S) generated by cystathionine gamma lyase enzyme 
(CSE) (Yang et al., 2008; Fang et al., 2009)as well as adipocyte-derived relaxing factor, 
adiponectin, leptin, omentin, and interleukin-6 (Fesus et al., 2007; Sahin and Bariskaner, 
2007; Yamawaki et al., 2010).  Taken together, the deregulation of the RAS in adipose 
associated with diminished AT1R expression in the vasculature might drive the subsequent 
hypotension observed in the ECahr
-/-
 mice. 
The ahr floxed mice (ahr
fx/fx
), which were our genetic control in these studies, 
harbor the low affinity, ahr
d
 allele, derived from the DBA-2 strain (Poland and Glover, 
1980).  In contrast, the ahr
+/+
 mice used as a genetic control in previously published 
studies harbor the high affinity, ahr
b1
 allele.  Thus, we cannot directly compare the blood 
pressure phenotype of the ECahr
-/-
 mice and ahr
-/-
 mice.  Nevertheless, the blood pressure 
phenotype of the ECahr
-/-
 and the ahr
-/-
 mice, compared to their respective wildtype 
controls, shares many similarities.  First, hypotension is a hallmark of both of these mouse 
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models (Zhang et al., 2010),  where the ahr
-/-
 mice exhibit a 14% lower MAP, compared 
to ahr
+/+
mice, while ECahr
-/-
 mice exhibit an 8% lower MAP, compared to ECahr
+/+
 mice.  
Second, the resultant hypotension in both ECahr
-/-
 and the ahr
-/-
 mice is not mediated by 
an increase in NO production. Third, both ECahr
-/-
 and the ahr
-/-
 mice exhibit a reduced 
responsiveness to the RAS without apparent changes in indices of RAS activation, 
suggesting that the RAS contributes less in maintaining basal blood pressure in both the 
ECahr
-/-
 and ahr
-/-
 mice (Zhang et al., 2010).       
Finally, ECahr
-/-
 and ahr
-/-
 mice also share some fundamental similarities related to 
in changes in organ weight.  The ahr
-/-
 mice exhibit decreased liver size, as well as 
increased weight of heart and kidneys (Lund et al., 2006; Zhang et al., 2010).  In our 
study, ECahr
-/-
 mice also exhibit a decreased liver size, as well as increased weight of heart 
and kidneys.  While the reduction in liver weight has been attributed to the persistent 
ductus venosus and reduced hepatocyte size (Lahvis et al., 2000; Lahvis et al., 2005), the 
reasons for the increases in heart and kidney weight have not been firmly established.  The 
increased heart weight might reflect a compensatory response to increase cardiac output in 
an attempt to normalize blood pressure, hence a physiological hypertrophy (Vasquez et 
al., 2003),  while increased kidney weight may result from altered developmental 
vascularization (Lahvis et al., 2000).  Nonetheless, our study demonstrates that these 
organ weight changes result from loss of AHR solely from the endothelium. 
The mechanism by which AHR regulates blood pressure remains to be fully 
determined; however, our study establishes that AHR expression in the endothelium is 
particularly critical to normal vascular responsiveness to Ang II and thus basal blood 
pressure control.  Since the RAS is not only essential to the physiological regulation of 
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basal blood pressure but also a primary pathological mediator of hypertension, the AHR 
signaling pathway could represent an important novel mechanism to influence RAS 
activity and to control blood pressure.  Future studies are needed, however, to identify the 
specific AHR genes that mediate these changes in RAS responsiveness and that influence 
the vascular responsiveness in the context of adipose tissue.  
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SUPPLEMENT DATA 
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Endothelial cell-specific aryl hydrocarbon receptor knockout mice exhibit 
hypotension mediated, in part, by an attenuated angiotensin II responsiveness. 
 
Larry N. Agbor, Khalid M. Elased, and Mary K. Walker. Biochem Pharmacol 5: 514–
523, 2011. 
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RNA isolation and qPCR analysis.  
Aortic eNOS mRNA was analyzed from total RNA by quantitative real time PCR 
using an Icycler (Bio-Rad), with PGK gene as an internal normalization control. Total 
RNA was isolated from aortas with RNeasy Fibrous Tissue Mini Kit (Qiagen, GmbH, 
Germany). cDNA was synthesized using iScript Select cDNA Synthesis Kit (Bio-Rad 
Laboratories,Hercules, CA) with the supplied random primers and 250 ng RNA. PCR 
amplification was performed using an iCycler (Bio-Rad Laboratories) with a reaction 
mixture comprised of iQ SYBR Green Supermix (Bio-Rad Laboratories) with 500 µM 
sense and antisense primers, and 250 pg cDNA.  Cycle threshold data for the target gene 
and reference, PGK, were used to calculate mean normalized expression. 
 
Protein extraction and western blot.   
Aortas were homogenized in RIPA buffer (Santa Cruz Biotechnology), 
homogenate frozen at -80 °C for 15 min, sonicated for 10 s and centrifuged at 15,000 x g 
4 °C for 10 min.  Protein concentration was measured using Bio-Rad protein assay (Bio-
Rad Laboratories).   A 20 µg aliquot of protein was mixed with 2× loading buffer (100 
mM pH6.8 Tris-HCl, 4% sodium dodecyl sulfate, 0.2% bromophenol blue, 20% glycerol, 
200 mM dithiothreitol) and denatured at 95 °C for 5 min.  Denatured samples were 
subjected to electrophoresis on 7.5% Tris-HCL polyacrylamide gel at 150 V for 1 hour in 
running buffer (25 mM Tris-base, 150 mM glycine, 0.1% sodium dodecyl sulfate) and 
separated proteins were transferred to polyvinylidene fluoride (PVDF) membrane (Bio-
Rad Laboratories) at 100 V for 1 hour in cold transfer buffer (20 mM Tris-base, 150 mM 
glycine, 20% methanol).  The membrane was washed with Tris-buffered saline (TBST, 
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0.8% NaCl, 0.02% KCl, 0.3% Tris-base, 0.05% Tween-20, pH7.4) and blocked for 1 
hour in 5% nonfat dry milk in TBST.  The blocked membrane was incubated with mouse 
anti-eNOS antibody (1:2000, Catalogue No. 610296, BD Transduction Laboratories, San 
Jose, CA) at 4 °C overnight, washed with TBST, and incubated with horseradish 
peroxidase (HRP) conjugated goat anti-mouse (Southern Biotech, Birmingham, AL) for 1 
hour at room temperature.  The membrane was washed with TBST and developed for 10 
min with 1 mL chemiluminescence reagent (Perkin-Elmer, Waltham, MA) under KODAK 
Image Station 4000MM digital imaging system (Perkin-Elmer).  The membrane was 
stripped (7 M guanidine hydrochloride, 0.75% KCl, 0.38% glycine, 50 µM EDTA, 0.14% 
2-mercaptoethanol, pH10), washed with TBST, reblocked, and incubated with mouse 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Millipore, Billerica, MA, USA) 
overnight, washed with TBST, incubated with HRP-conjugated goat anti-mouse IgG 
(Southern Biotech), washed and developed as above.  Protein quantification was done 
using Image J software (National institute of Health, USA) 
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Figure. 2.1S. Hypotension in ECahr
-/-
 mice is not associated with increased eNOS 
expression nor increased NO bioavailability. (A) Aortic eNOS mRNA from ECahr
-/-
 and 
ECahr
+/+
 mice as measured by qPCR and normalized to PGK. (B) Representative western 
blot of total eNOS protein expression from aorta, (C) quantification of  total eNOS 
protein expression relative to GAPDH, and (D) urinary NOx of ECahr
+/+
 and ECahr
-/-
 
mice (n=5/genotype) .  Data represent mean ± SEM and were analyzed by Student’s t-test. 
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Figure. 2.2S. Loss of AHR in endothelial cells enhances sympathetic innervation to the 
vasculature. (A) Change in blood pressure following prazosin and hexamethonium 
treatment was calculated by averaging readings for 30 mins after injections, and expressed 
as change from baseline MAP.  (B) Basal and intrinsic heart rate following 
hexamethonium injection.  Data represent mean ± SEM and were analyzed by Student’s t-
test; *p < 0.05, compared to ECahr
+/+
, n=5/genotype. 
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Table 1S: Real Time PCR primer sequences 
Gene Sense primer Antisense primer (s) 
 
DNA Polymerase 2 (POL2) 
 
TGACTCACAAACTGGCTGACATT 
 
TACATCTTCTGCTATGACATGGGC 
 
AT1R GGGCGTCATCCATGACTGTAAA TTCCCCAGAAAGCCGTAAAACA 
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) 
CCAATGTGTCCGTCGTGGATC TGTAGCCCAAGATGCCCTTCA 
 
 
Renin ATGAATATGTTGTGAGCTGTAGCC GTCTCTCCTGTTGGGATACTGTAG 
 
Angiotensinogen CACTCATTTGTTCAGAGCCTGG GTTCATCTTCCACCCTGTCACA 
 
Cre recombinase (cre) TGCCTGCATTACCGGTCGATGC CCATGAGTGAACGAACCTGGTCG 
 
Aryl hydrocarbon receptor 
genotyping primers (ahrfx/fx)  
 
Endothelial nitric oxide 
Synthase (eNOS) 
GTCACTCAGCATTACACTTTCTA 
 
 
GCCAAAGTGACCATAGTGGACC 
CAGTGGGAATAAGGCAAGAGTGA/ 
/GGTACAAGTGCACATGCCTGC 
 
TTCTGCTCATTTTCCAGGTGCTT 
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Table 2S: Adipose weights of 2-month-old male 
ECahr
+/+
 and ECahr
-/-
 mice.   
Adipose 
 
ECahr
+/+
 
(n=8) 
ECahr
-/-
 
(n=5) 
 
Mesentery (mg)  
 
 
 65.7 ± 5.9 
(0.249 ± 0.02)
†
 
 
44.1 ± 8.9 
(0.177± 0.01)
†
 
 
Perirennal (mg) 123.6 ± 9.5 
(0. 107 ± 0. 
008) 
91.6 ± 4.3 
      (0.125 ±0.02)
 
†
 
 
PVAT (mg) 28.1 ± 2.1 
(0.469 ± 0.03)
†
 
31.0 ± 4.9 
(0.369 ± 0.04)
†
 
   
   
Values are expressed as mean ± SEM 
†
 (Adipose/body weight ratio x 100) 
Legend: PVAT, Perivascular adipose tissue.  
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III. CHAPTER 3 
Elevated blood pressure in cytochrome P4501A1 (CYP1A1) knockout mice is 
associated with reduced vasodilation to omega-3 polyunsaturated fatty acids. 
In preparation for submission to Toxicology and Applied Pharmacology 
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A. ABTRACT 
Cytochrome P4501A1 (CYP1A1) metabolizes omega-3 polyunsaturated fatty 
acids (n-3 PUFAs); eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), to 
potent vasodilators in vitro.  Although CYP1A1 is constitutively expressed in the 
vasculature, its role in regulating vascular tone and blood pressure (BP) has not been 
investigated.  Thus, we tested the hypothesis that global genetic deletion of CYP1A1 will 
result in reduced vasodilatory responses to n-3 PUFAs and increases in BP.  We assessed 
BP by radiotelemetry in CYP1A1 wild type (WT) and knockout (KO) mice ± nitric oxide 
synthase (NOS) inhibitor (N
ω
-nitro-L-arginine).  Acetylcholine (ACh), EPA, DHA, 19,20-
epoxydocosapentaenoic acid (19,20-EDP), and 17,18-epoxyeicosatetraenoic acid (17,18-
EEQ)-mediated vasorelaxation was assessed in the aorta and first order mesenteric 
arterioles.  Further, S-nitroso-N-acetylpenicillamine (SNAP)-mediated relaxation was 
assessed in endothelium-disrupted aorta and DHA-mediated relaxation was assessed in 
mesenteric arterioles ± inhibitors of the voltage-gated (Kv), and large conductance, 
calcium-activated potassium channels (BK).  We found that CYP1A1 KO mice were 
hypertensive, compared to WT mice (mean arterial pressure in mmHg, WT 103±1, KO 
116±1; systolic BP: WT 114±1, KO 124±1; diastolic BP: WT 93±1, KO 108±1, 
n=5/genotype, p<0.05), and exhibited a reduced HR (in beats per minute, WT 575±5; KO 
530±7; p<0.05).  Nonetheless, CYP1A1 KO mice exhibited normal responses to NOS 
inhibition and aortic vasorelaxation to ACh and SNAP, suggesting that hypertension is not 
associated with loss of NO.  Conversely, CYP1A1 KO mice exhibited significant 
attenuation to EPA and DHA-mediated vasodilation in mesenteric arterioles and aorta, but 
normal vasodilatory responses to putative CYP1A1 metabolites of EPA and DHA, 17,18-
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EEQ and 19,20-EDP .  Lastly, inhibition of Kv and BK channels significantly inhibited 
DHA-mediated vasodilation in mesenteric arterioles.  These data suggest that constitutive 
CYP1A1 expression has a physiologically important role in the regulation of vascular 
function and blood pressure, which may involve vasodilatory responses to n-3 PUFAs. 
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B.         INTRODUCTION 
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are metabolized by numerous 
cytochrome P450s into several products that have potent vasodilatory properties 
(Schwarz et al., 2004; Schwarz et al., 2005).  Some of these metabolites have been 
recognized to play key roles in contributing to underlying vascular tone, BP, and overall 
cardiovascular health (Billman et al., 1994; Engler et al., 1999; Menotti et al., 1999; 
Blanchet et al., 2000).  Nonetheless, the contribution of specific P450s to the regulation of 
vascular tone and BP via n-3 PUFA metabolism remains poorly understood.  
Cytochrome P4501A1 (CYP1A1) is one P450 shown to metabolize n-3 PUFAs to 
vasodilatory products.  CYP1A1 is constitutively expressed in vascular endothelium with 
CYP1A1 mRNA and protein levels detected in cultured human umbilical vein endothelial 
cells as well as in endothelial cells of the mouse descending thoracic aorta, and human 
coronary arteries (Eskin et al., 2004; Han et al., 2008; Conway et al., 2009).  In addition 
to its basal expression in the endothelium, CYP1A1 is also induced in the endothelium by 
physiological levels of shear stress (Han et al., 2008; Conway et al., 2009).  Physiological 
laminar shear stress is considered to be anti-atherogenic  (Cunningham and Gotlieb, 2004).  
It significantly induces antioxidants, antithrombotic factors, and vasodilators, such as nitric 
oxide (NO) and prostacyclin, and suppresses prothrombotic substances and 
vasoconstrictors.  This raises the possibility, as suggested by Conway et al. (2009) and De 
Caterina and Madonna (2009), that physiological induction of CYP1A1 in the endothelium 
could also contribute to the anti-atherogenic phenotype and that this may be mediated via 
metabolism of PUFAs.  Parallel increases in CYP1A1 and NO have also been observed in 
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cultured endothelial cells treated with an aryl hydrocarbon receptor agonist (Lim et al., 
2007). 
As noted above, evidence from several studies show that CYP1A1 metabolizes 
two major n-3 PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in 
a stereospecific manner.  Human CYP1A1 epoxidizes the 17,18-olefinic bond of EPA in a 
regiospecific manner to form mainly 17(R),18(S)-epoxyeicosatetraenoic acid 
[(17(R),18(S) EEQ)] (Schwarz et al., 2004).  CYP1A1 also exclusively epoxidizes the 
19,20-olefinic bond of DHA, producing 19(R),20(S)-epoxydocosapentaenoic acid 
[19(R),20(S)-EDP] (Fer et al., 2008; Lucas et al., 2010).  Furthermore, both of these 
metabolites, 17,18-EEQ and 19,20-EDP, are potent vasodilators in the microcirculatory 
vessels  of the pig and/or mouse (Zhang et al., 2001), and 17,18-EEQ causes relaxation 
and hyperpolarization of pulmonary artery smooth muscle (Morin et al., 2009).  Studies 
have identified a variety of downstream mechanisms that mediate this vasodilation, 
including increases in NO signaling (Ma et al., 2004; Li et al., 2007a; Stebbins et al., 
2008) as well as activation of potassium channels on vascular smooth muscle cells 
(Lauterbach et al., 2002; Ye et al., 2002; Wang et al., 2011).  
Taken together, these data suggest that CYP1A1 could metabolize DHA and EPA 
as substrates in vivo into vasodilatory metabolites that act via NO or potassium channel 
activation.  Thus, we sought to determine the degree and mechanism by which CYP1A1 
contributes to vascular responses to n-3 PUFAs and to BP regulation.  We used CYP1A1 
wild type (WT) and knockout (KO) mice to test the hypothesis that global genetic deletion 
76 
 
of CYP1A1 will result in reduced vasodilatory responses to n-3 PUFAs and increases in 
BP. 
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C. METHODS 
Chemicals 
Acetylcholine (ACh), phenylephine (PE), N
ω
-nitro-L-arginine (LNNA), S-nitroso-
N-acetyl penicillamine (SNAP), 4-aminopyridine, iberiotoxin, and all ingredients of 
physiological saline solution (PSS) and HEPES-PSS were purchased from Sigma–Aldrich 
(St. Louis, MO).  EPA, DHA, 17,18-EEQ, 19,20-EDP and U46619 were purchased from 
Cayman Chemical (Ann Arbor, MI).  Ionomycin was purchased from EMD Millipore 
Chemicals (San Diego, CA). 
 
Animals 
CYP1A1 KO mice, backcrossed more than eight generations onto the C57BL/6J 
background, were generously provided by Dr.  Daniel Nebert (University of Cincinnati) 
and were bred at the University of New Mexico (Dalton et al., 2000).  Age-matched 
C57BL/6J mice served as WT controls.  Animals were housed in a temperature-controlled 
environment receiving standard mouse chow and water ad libitum.  All animal protocols 
were approved by the University of New Mexico Animal Care and Use Committee and the 
investigations conform to the Guide for the Care and Use of Laboratory Animals 
published by the U. S. National Institutes of Health (NIH Publication No.  85-23, revised 
1996).  When tissues were harvested and organ weight determined, mice were 
anesthetized with ketamine (80 mg/kg)/xylazine (4 mg/kg).  The heart was removed, atria 
were dissected, and the total ventricle weight measured.  The right ventricle was dissected 
and the left ventricle and ventricular septum measured.  Kidneys and liver weights were 
also measured.  All tissues were frozen at −80°C.  
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In vivo analysis of blood pressure 
Arterial BP and heart rate (HR) were measured using radiotelemetry in 4-5 month-
old CYP1A1 WT and KO male mice (Data Sciences International, St. Paul, MN, USA) as 
previously described (Lund et al., 2008), using PA-C10 radiotelemeters.  Mice were 
allowed to recover from surgery for 7 d prior to data collection.  BP, including systolic, 
diastolic, mean and pulse pressures, and HR were collected for 7 d before drug treatments 
began.  BP was recorded for 10 s every 15 min during baseline measurements.  After basal 
BP was measured, all mice were treated with LNNA in the drinking water (250 mg/L) for 
one week followed by one week of washout (Duling et al., 2006). 
 
Aortic vasoreactivity analysis 
Mice were anesthetized with ketamine (80 mg/kg)/xylazine (4 mg/kg) and 
euthanized by exsanguinations.  Either the thoracic or abdominal aorta was removed, 
depending on the study, and placed in ice-cold physiological saline (PSS) containing 130 
mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 15 mM NaHCO3, 5.5 mM 
glucose, 26 mM CaNa2EDTA, 1.8 mM CaCl2, pH 7.4, and cleaned of connective tissue 
and adventitial fat.  The vessel was cut into 3 mm segments and individual rings were 
suspended in an organ bath containing PSS at 37 
0
C bubbled with 21% O2, 6% CO2, 
balanced N2.  The rings were attached to a force transducer (Grass Technologies, West 
Warwick, RI) with steel hangers and resting tension was increased stepwise to 1.5 g over 
1 h.  In thoracic aorta, after an initial contraction with 10 mM PE followed by relaxation 
with 10 mM ACh, dose-response curves to PE (0.001–10 mM), or PE following a 30 min 
preincubation with the NOS inhibitor, LNNA (100 µM) was performed.  An ACh dose- 
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response (0.001–10 mM) was also conducted in the thoracic aorta following 
preconstriction with PE (30 µM).  In endothelium-disrupted thoracic aorta, a dose-
response to the NO donor, SNAP (0.001–10 mM) was also conducted.  In abdominal 
aorta, DHA and EPA dose-response studies (0.001–10 mM) were conducted following 
preconstriction with the thromboxane A2 mimetic, U46619.  Lastly, dose-response curves 
to 17,18-EEQ, and 19,20-EDP (10
-5 
-10 nM) were conducted in the abdominal aorta 
preconstricted with U46619.  
 
Mesenteric vasoreactivity analysis 
Mice were administered heparin (10 µl/g of 1000 U/ml) by intraperitoneal injection 
for 5 min, anesthetized with ketamine (80 mg/kg)/xylazine (4 mg/kg), and euthanized by 
exsanguination.  The intestine together with mesenteric arteries were quickly excised and 
placed in HEPES-PSS solution (134 mM NaCl, 6.0 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 
10 mM HEPES, 0.026 mM EDTA, 10 mM glucose, and buffered to pH 7.4 with NaOH).  
The tissue was then pinned to the bottom of a petri dish, and a long segment of a first-
order branch of the mesenteric artery was cleared from surrounding adipose tissue and 
dissected.  The artery was transferred to the chamber of a pressure myograph system 
(DMT -110 systems, Danish Myo Technology, Ann Harbor, MI) for cannulation.  The 
chamber was filled with warm PSS at 37 
0
C bubbled with 21% O2, 6% CO2, balanced N2 
(130 mM NaCl, 4.7 mM KCl, 1.18 mM KH2PO4, 1.17 mM MgSO4, 14.9 mM NaHCO3, 
5.5 mM glucose, 26 µM CaNa2EDTA, and 1.8 mM CaCl2, pH 7.4).   One end of the 
vessel was cannulated with the outflow pipette and tied securely with 10-0 ethilon surgical 
silk thread.  The other end of the vessel was then cannulated with the inflow pipette.  The 
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pressure was then increased by 10 mmHg increment every 5 mins to a maximum of 40 or 
60 mmHg, and the artery allowed to equilibrate for 30 min.  After equilibration, baseline 
internal diameter (WT 167.9 ± 3.3, KO 171.7± 3.1) was measured using edge detection 
software (MyoView acquisition software, DMTVAS 6.2.0.59 Danish Myo Technology, 
Ann Harbor, MI).  In other vessels, passive internal diameter (WT 178.3 ± 5.1, KO 181.4 
± 2.0) was also determined after preincubation with the calcium ionophore, ionomycin (10 
µM) for 15 mins.  Viability of the arteries was tested by constriction to 60 mM KCl and 
vessels that failed to constrict to 30% of baseline internal diameter were discarded.  After 
a PSS wash, the artery was allowed to return to baseline diameter and to rest for at least 
15 min.  Arteries were then preconstricted to 45% of internal diameter with U46619, and 
a dose-response to EPA (0.001–100 mM) and DHA (0.001–100 mM) conducted.  In 
other vessels, a DHA dose-response was conducted after preincubation with 100 nM 
Iberiotoxin (IBTX) ± 4-aminopyridine (4-AP) (5 mM).  Further, a dose-response to 
U46619 (0.01-1 µM) was also conducted.  Lastly, we assessed dose-responses to 17,18-
EEQ and 19,20-EDP (10
-5
 -10 nM).  All experiments were performed without luminal 
flow. 
Plasma NOx analyses 
 
Mice were anesthetized with ketamine (80 mg/kg)/xylazine (4 mg/kg) and 
euthanized by exsanguination.  Plasma was collected from whole blood using heparinized 
syringes.  Plasma nitrate/nitrite levels (NOx) were measured using the Griess colorimetric 
assay (Cayman Chemical).    
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mRNA analysis of potassium channel subunits, CYP2C29, CYP2E1, CYP2D6 and COX2 
 
Total RNA was isolated from aorta cleaned of connective tissue and adventitial fat, 
using Trizol reagent (Invitrogen, Carlsbad, CA, USA).  cDNA was synthesized using 
iScript Select cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA) with the 
supplied random primers and 250 ng RNA.  PCR amplification was performed using an 
iCycler (Bio-Rad Laboratories) with a reaction mixture comprised of iQ SYBR Green 
Supermix (Bio-Rad Laboratories) with 500 μM of each forward and reverse primer (Table 
3.1).  Cycle threshold data for both the target gene of interest and control normalization 
gene, DNA Polymerase II (POL2) was used to calculate mean normalized expression as 
previously described (Simon, 2003).  
Statistical analysis 
 
Differences between genotypes were analyzed by Student’s test.  The treatment-
related changes in BP and vasoreactivity between genotypes were analyzed by repeated 
measures, two-way analysis of variance with post hoc Holm-Sidak comparisons; p < 0.05 
was considered statistically significant.  
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D. RESULTS 
Body and organ weights 
We compared body and organ weights of CYP1A1 WT and KO mice.  CYP1A1 KO mice 
exhibited significantly lower body weights, compared with age-matched CYP1A1 WT 
mice (Table 3.2).  All organs weighed from CYP1A1 KO mice, including heart, kidneys 
and liver, were significantly smaller than WT.  When organ weight was normalized to 
body weight, the liver/body weight and kidney/body weight ratios remained significantly 
lower in CYP1A1 KO mice, compared to WT mice.  
 
Basal blood pressure, heart rate, and activity  
BP of CYP1A1 WT and KO mice was measured by radiotelemetry.   The CYP1A1 
KO mice exhibited significantly higher systolic and diastolic BPs, compared to WT (Fig. 
3.1A).  Corresponding HR was significantly lower in CYP1A1 KO mice, compared to WT 
(Fig. 3.1B).  When assessed over a 24 h light/dark cycle, the increase in systolic BP in 
CYP1A1 KO mice was evident only at nighttime (Fig. 3.1C).   In contrast, diastolic BP 
was significantly increased in CYP1A1 KO mice throughout the entire 24 h light/dark 
cycle, although the normal circadian pattern of an increased BP during the night wakeful 
period was preserved (Fig. 3.1D).  The level of activity was comparable between CYP1A1 
WT and KO mice over the 24 h light/dark cycle (Fig. 3.1E).   Finally, the difference 
between mean nighttime and mean daytime arterial pressure (MAP) was significantly 
higher in CYP1A1 KO mice, compared to WT (Fig. 3.1F).    
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Table 3.1.  Real-time PCR primer sequences 
 
Gene Sense Primer Antisense Primer 
   
BKα subunit TCACGGAACTCGCTAAGCC AATGTGCGTCCCACTGTTTTT 
BKβ4 subunit GCGAAGCTCAGGGTGTCTTAC CCGGAGACGATGAGGAACAA 
Kv1.5 subunit TCCGACGGCTGGACTCAATAA GCCTCCTCGGTGATGTTTCT 
CYP2C29 TGGTCCACCCAAAAGAAATTGA GCAGAGAGGCAAATCCATTCA 
COX2 
CYP2E1 
 
CYP2D6 
TGCCTGGTCTGATGATGTATGCCA 
TGCGGAGGTTTTCCCTAAGTA 
CCGCCTTCGCTGACCATAC 
 
AGTATGTCGCACACTCTGTTGTGCT 
TGTGCCTCTCTTTGGATGCG 
CGATCACGTTACACACTGCTT 
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Table 3.2.  Gross tissue weight measurements in 4 month-old CYP1A1 WT and KO mice 
 
 
Weight CYP1A1 WT 
(n=5) 
CYP1A1 KO 
(n=5) 
Body (g) 
 
29.4 ± 0.4 23.6 ± 0.3* 
Heart (mg) 129 ± 4 
(0. 439 ± 0. 024)
 
†
 
107 ± 3* 
(0. 452 ± 0. 
029) 
LV+S (mg) 101 ± 4 
(0. 343 ± 0. 022)
 
 
84.5 ± 3* 
(0. 356 ± 0. 
024)
 
 
Kidney (mg) 425 ± 11 
(2.13 ± 0. 024) 
293 ± 10* 
(1.54 ± 0. 003)
 
* 
Liver (mg) 
 
1671 ± 42 
(5.6 ± 0. 014)
 
 
1215 ± 31* 
(5.1 ±0. 089)* 
Values are expressed as mean ± SEM 
* p < 0.05 
†
(Organ/body weight ratio x 100) 
Legend: LV+S, Left ventricle + Septum.  
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Figure 3.1.  Genetic deletion of CYP1A1 increases systolic and diastolic BP, and reduces 
HR. (A) 24 h mean systolic and diastolic BP, (B) 24 h mean HR, (C) Hourly systolic 
pressure over a 24 hr period (light and dark cycle), (D) Hourly diastolic pressure over a 24 
hr period (light and dark cycle), (E) Activity over a 24 hr period, and (F) Difference in 
MAP between nighttime and daytime, as measured by radiotelemetry.  Data represent 
mean ± SEM.  Data in A, B, and F were analyzed by Student’s t-test; *p < 0.05, and in C, 
D and E by two-way, repeated measures ANOVA, using post hoc Holm-Sidak 
comparisons; *p < 0.05 (n=7/genotype) 
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Vascular reactivity in aorta and mesenteric resistance arterioles 
We sought to determine if genetic deletion of CYP1A1 resulted in altered vascular 
responses indicative of a loss of the endothelial-derived vasodilator, NO.  Since ACh-
mediated vasorelaxation in the thoracic aorta is dependent solely on NO (Rees et al., 
1989), we conducted a dose-response to ACh in aortic segments preconstricted with PE.  
We found that CYP1A1 KO mice exhibited completely normal vasorelaxation responses 
to ACh (Fig 3.2A).  To confirm that NO-mediated signaling was normal in the vascular 
smooth muscle, we next conducted a dose-response to the NO donor, SNAP, in 
endothelium-disrupted aortic segments.  Again, CYP1A1 KO mice exhibited completely 
normal responses to SNAP (Fig. 3.2B).  Lastly, if NO was reduced we would expect 
constrictor responses to be enhanced and the enhancement eliminated by treatment with a 
NOS inhibitor.  We found that CYP1A1 KO mice exhibited normal vasoconstriction 
responses to PE with and without a NOS inhibitor, LNNA (Fig. 3.2C and D).   Since 
ACh-mediated dilation in resistance vessels also is dependent on NO to a limited degree, 
we conducted a dose response to ACh in first-order pressurized mesenteric arterioles.  
Again CYP1A1 KO mice exhibited completely normal vasodilation responses to ACh, 
suggesting that NO-dependent dilation is also not altered in resistance vessels (Fig. 3.2E). 
 
Plasma NOx and effects of NOS inhibition on blood pressure. 
To further confirm whether a reduction in NO bioavailability contributed to the 
hypertension in CYP1A1 KO mice, we measured plasma NOx as an indicator of systemic 
NO and we treated CYP1A1 WT and KO mice with a NOS inhibitor and measured their 
BP responses.  We found that CYP1A1 KO mice tended to have reduced plasma NOx 
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(p=0.07), although it was not statistically different (data not shown).   Further, NOS 
inhibition failed to normalize BP between CYP1A1 WT and KO mice.  Hourly MAP over 
a 24 hr period (light and dark cycle) after NOS inhibition showed that CYP1A1 KO mice 
remain hypertensive (Fig. 3.3A) and the relative change in MAP was equivalent between 
CYP1A1 KO and WT (Fig. 3.3B). 
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Figure 3.2.  Loss of CYP1A1 does not affect vascular sensitivity to ACh- or SNAP-
mediated dilation, nor PE-mediated contraction in the absence or presence of the NOS 
inhibitor, LNNA (A)-(D) thoracic aorta, (E) mesenteric arterioles.  (A) ACh-mediated 
dilation (% PE preconstriction), (B) SNAP-mediated dilation in endothelium denuded 
aorta (% PE preconstruction), (C) PE-mediated constriction (% KCl), and (D) PE-
mediated constriction in the presence of LNNA, (E) ACh-mediated relaxation (% U46619 
preconstriction).  Data represent mean ± SEM and were analyzed by two-way, repeated 
measures ANOVA, using post hoc Holm-Sidak comparisons (n=7-8/genotype).   
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Figure 3.3.  NOS inhibition by LNNA does not normalize BP in CYP1A1 KO mice in 
vivo. (A)  MAP over a 24 hr period (light and dark cycle) after NOS inhibition. (B) 
Change in MAP from baseline after treatment with 250 mg/L LNNA in drinking water of 
male CYP1A1 KO and wildtype mice.  Data represent mean ± SEM and were analyzed by 
two-way, repeated measures ANOVA, using post hoc Holm-Sidak comparisons; *p < 
0.05, compared to wildtype (A), and by Student’s t-test (B) (n=5/genotype).  
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DHA- and EPA-mediated vasorelaxation and vasodilation are attenuated in abdominal 
aorta and mesentery arteries, respectively, of CYP1A1 KO mice 
Given that our previous results ruled out a loss of NO bioavailability as a 
contributor to hypertension in CYP1A1 KO mice, we next sought to determine if vascular 
reactivity to n-3 PUFAs; DHA and EPA, was altered.  We assessed the vasodilation 
responses in abdominal aorta and pressurized mesenteric arterioles to DHA and EPA.  
CYP1A1 KO mice exhibited significantly attenuated dose-dependent vasorelaxation to 
both DHA and EPA in the aorta (Fig. 3.4A and B).  Similarly, CYP1A1 KO mice 
exhibited significantly reduced dose-dependent vasodilation to DHA and EPA in 
mesenteric arterioles when pressurized at 40 (Fig. 3.5A and B) or 60 mmHg (Fig. 3.5C 
and D).  
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Figure 3.4.  DHA and EPA-mediated vasorelaxation are significantly attenuated in 
abdominal aorta of CYP1A1 KO mice.  (A) DHA-mediated relaxation (% U46619 
preconstriction), (B) EPA-mediated relaxation (% U46619 preconstriction), in abdominal 
aorta from CYP1A1 WT and KO and wildtype mice.  Data represent mean ± SEM and 
were analyzed by two-way, repeated measures ANOVA, using post hoc Holm-Sidak 
comparisons; *p < 0.05, compared to wildtype ((n=6/genotype). 
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 Figure 3.5.  DHA and EPA-mediated vasorelaxation are attenuated in pressurized 
mesenteric resistance arteries at both 40 and 60 mmHg.  (A) DHA-mediated relaxation at 
40 mmHg, (B) EPA-mediated relaxation at 40 mmHg, (C) DHA-mediated relaxation at 60 
mmHg, and (D) EPA-mediated relaxation at 60 mmHg.  All relaxation experiments were 
subjected to U46619 preconstriction.  Data represent mean ± SEM and were analyzed by 
two-way, repeated measures ANOVA, using post hoc Holm-Sidak comparisons; *p < 
0.05, compared to wildtype (n=8-14/genotype). 
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CYP1A1metabolites of EPA and DHA (17,18-EEQ and 19,20-EDP, respectively) are 
potent vasodilators in the abdominal aorta and mesenteric arterioles. 
If CYP1A1 mediates n-3 PUFA vasodilation by generating the 17,18-EEQ and 
19,20-EDP metabolites as has been demonstrated in vitro, then we would expect that the 
ability of these metabolites to produce vasodilation when applied directly to the vessel 
would not differ between genotypes.  Thus, we assessed vasorelaxation of the abdominal 
aorta and vasodilation of mesenteric arterioles to 17,18-EEQ and 19,20-EDP.  We found 
that 17,18-EEQ and 19,20-EDP elicited potent and highly efficacious vasorelaxation 
responses in the aorta of both CYP1A1 WT and KO  mice at nanomolar concentrations 
(Fig. 3.6A and B).  In mesenteric arterioles, both metabolites were less potent in inducing 
vasodilation compared to the aorta, and 17,18-EEQ was significantly less efficacious.  
Nonetheless, the responses elicited in both CYP1A1 WT and KO mesenteric arterioles 
were equivalent (Fig. 3.6C and D).  
 
Voltage-gated (Kv) and large conductance, calcium-activated potassium (BK) channels 
are targets for DHA-mediated vasodilation 
Since previous studies have implicated the activation of potassium ion channels in 
mediating vasodilation to n-3 PUFA, we investigated the contribution of two of these 
channels to vasodilation in CYP1A1 WT and KO mice.  We preincubated mesenteric 
arterioles with a blocker of the BK channel, IBTX, in the absence or presence of an 
inhibitor of the Kv channel, 4-AP, and then conducted a dose-response with DHA.  We 
found that both CYP1A1 WT and KO mesenteric arterioles elicited vasodilation to DHA 
in the presence of the BK channel blocker (Fig. 3.7A and B).  Nonetheless, blockade of 
94 
 
both BK and Kv channels significantly inhibited DHA-mediated vasodilation in both 
CYP1A1 WT and KO mice (Fig. 3.7C and D).  
 
mRNA analysis of Kv and BK channel subunits, CYP2C29, CYP2E1, CYP2D6 and COX2 
 
To determine if aortic expression of BK and Kv channel subunits, as well as 
several vascular P450s involved in n-3 PUFA metabolism, CYP2C29, CYP2E1, CYP2D6, 
and COX2 were altered in their expression, we measured mRNA of BKα, BKβ4, Kv1.5, 
CYP2C29, CYP2E1, CYP2D6 and COX2 in aortas of CYP1A1 KO and WT mice 
cleaned of adipose tissue.  We did not find any differences in the mRNA expression of 
these potassium channel subunits or P450 (data not shown).  In contrast, COX2 mRNA 
expression was significantly lower by two fold in the aorta of CYP1A1 KO mice, 
compared to WT mice (data not shown).
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Figure 3.6.  P450 metabolites of EPA and DHA, 17,18-EEQ and 19,20-EDP,  
respectively, induce an equivalent degree of vasorelaxation in the abdominal aorta and 
vasodilation in mesenteric arterioles in CYP1A1 WT and KO mice.  Vasorelaxation in 
abdominal aorta to 17,18-EEQ (A) and to 19,20-EDP (B).  Vasodilation in mesenteric 
resistance arterioles to 17,18-EEQ (C), and 19,20-EDP (D).  Data represent mean ± SEM 
and were analyzed by two-way, repeated measures ANOVA, using post hoc Holm-Sidak 
comparisons; *p < 0.05, compared to WT (n=6-8/genotype). 
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Figure 3.7.  Voltage-gated (Kv) and large conductance calcium-activated potassium (BK) 
channels are targets for DHA-mediated vasodilation in mesenteric resistance arteries in 
both CYP1A1 WT and KO mice. DHA-mediated vasodilation after pre-incubation with 
the BK channel blocker, iberiotoxin (IBTX) in CYP1A1 WT (A), and KO mice (B).  
DHA-mediated relaxation after pre-incubation with both IBTX and the voltage gated 
potassium blocker, 4-aminopyridine (4-AP) in CYP1A1 WT (C) and KO mice (D).  Data 
represent mean ± SEM and were analyzed by two-way, repeated measures ANOVA, using 
post hoc Holm-Sidak comparisons; *p < 0.05, compared to wildtype (n=4-6/genotype). 
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E. DISCUSSION 
Our study shows for the first time that constitutive expression of CYP1A1 is 
required to maintain normal levels of BP and to mediate vasodilation responses to n-3 
PUFAs ex vivo.  CYP1A1 KO mice are hypertensive with a reduced HR.  Additionally, 
they exhibit attenuated vasodilation to the n-3 PUFAs, EPA and DHA, in both conduit 
arteries as well as resistance arterioles.  Notably, the putative CYP1A1 metabolites of 
EPA and DHA, 17,18-EEQ and 19,20-EDP, respectively, exhibit equivalent vasodilatory  
effects in CYP1A1 WT and KO mice, demonstrating that downstream signaling pathways 
are not altered by loss of CYP1A1.  Finally, although DHA-induced vasodilation was 
attenuated in CYP1A1 KO mice, compared to WT, our results suggest that this 
vasodilation is mediated by activation of potassium channels in both genotypes, further 
suggesting that the loss of n-3 PUFA-mediated vasodilation in CYP1A1 KO mice is not a 
result of changes in the downstream signaling pathways.   
Despite evidence that CYP1A1 is expressed in the vascular endothelium and highly 
induced by physiological shear stress (Han et al., 2008; Conway et al., 2009), the role of 
CYP1A1 in the regulation of blood pressure has never been investigated previously.  We 
found that CYP1A1 KO mice exhibit significantly elevated systolic and diastolic blood 
pressure.  Interestingly, systolic blood pressure is significantly increased only at night 
when the mice are active.  Since physical activity is associated with increased levels of 
physiological shear stress, this would suggest that CYP1A1 plays a role in the blood 
pressure responses to activity and physiological shear stress.  In addition, we found that 
CYP1A1 KO mice exhibit significantly elevated diastolic blood pressure throughout the 
entire 24 h light/dark cycle.  This would suggest that CYP1A1 also plays a role in the 
98 
 
overall regulation of peripheral vascular resistance, which would be consistent with a 
decrease in HR as a compensatory response.  Nonetheless, future studies that assess 
cardiac output and stroke volume, or use of flow probes would be needed to confirm if, in 
fact, peripheral vascular resistance is increased. 
 Despite evidence that CYP1A1 and NO are induced simultaneously by 
physiological shear stress in the endothelium (Malek et al., 1999; Boo et al., 2002a; Boo 
et al., 2002b; Eskin et al., 2004; Han et al., 2008; Conway et al., 2009) and that n-3 
PUFAs mediate vasodilation, in part, via increases in NO (Ma et al., 2004; Li et al., 
2007a; Stebbins et al., 2008), the increase in BP in CYP1A1 KO mice is not a result of a 
loss of NO.  In fact, multiple lines of evidence demonstrate that NO bioavailability and 
signaling are normal in CYP1A1 KO mice.  We found that ACh-mediated dilation in the 
thoracic aorta, which is exclusively NO-dependent (Rees et al., 1989), is normal in 
CYP1A1 KO mice as is the dilation response to a NO donor.  Most convincingly, 
treatment of CYP1A1 WT and KO mice with a NOS inhibitor does not normalize BP 
between the two genotypes, demonstrating that NO contributes equally to BP regulation. 
Since constitutive expression of CYP1A1 is regulated by the AHR as is shown in 
the AHR KO mice, it might be expected that AHR KO and CYP1A1 KO mice would 
exhibit similar BP phenotypes.  However, this is not the case.  Our data show that genetic 
deletion of CYP1A1 is associated with elevated BP, in contrast to reduced blood pressure 
(i.e. hypotension) observed for global AHR KO mice (Zhang et al., 2010) as well as the 
endothelial cell-specific AHR conditional KO mice (Agbor et al., 2011).  This suggests 
that multiple downstream targets regulated by the AHR are involved in BP regulation.  
One of these targets, in addition to CYP1A1, could be CYP1B1.  CYP1B1 is 
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constitutively expressed in vascular smooth muscle, and although CYP1B1 KO mice have 
normal blood pressure, they show a significantly attenuated response to angiotensin II-
induced hypertension (Jennings et al., 2010).  Thus, constitutive expression of CYP1B1 
may be pro-hypertensive, while that of CYP1A1 is pro-hypotensive. 
The involvement of P450s in blood pressure regulation is not unique to CYP1A1.  
Genetic deletion of CYP2J5 is associated with increased BP and overt afferent arteriolar 
responses to angiotensin II and endothelin I (Athirakul et al., 2008).  In addition, loss of 
CYP4A10 in mice is associated with a hypertensive phenotype which is salt-sensitive 
(Nakagawa et al., 2006).  Further, mice in which CYP4A14 is deleted are also 
hypertensive (Holla et al., 2001), associated with an increase in renal CYP4A12 
expression and an increase in the production of the potent vasoconstrictor, 20-
hydroxyeicosatetraenoic acid (Carroll et al., 1996).  Nonetheless, to the best of our 
knowledge, other P450s that have been shown to metabolize n-3 PUFAs in a 
stereospecific manner in vitro have not been investigated for their contribution to BP 
regulation in vivo (Lucas et al., 2010; Westphal et al., 2011).  
Our study also provides the first in vivo evidence that constitutive expression of 
CYP1A1 mediates, in part, the vasodilatory properties of n-3 PUFAs, EPA and DHA, in 
both conduit arteries and resistance arterioles. This result is highly consistent with the in 
vitro studies demonstrating that recombinant human CYP1A1 metabolizes EPA and DHA 
stereospecifically into products with vasodilatory properties (Fer et al., 2008; Lucas et al., 
2010).  Schwarz et al. (2004) show that 17(R),18(S)-EEQ  represents 70% of the 
products produced by human CYP1A1 metabolism of EPA, while 19(R),20(S)-EDP is the 
only product produced by human CYP1A1 metabolism of DHA (Fer et al., 2008).  While 
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it is not known if mouse CYP1A1 also shows this same degree of specificity in EPA and 
DHA metabolism, our results strongly suggest that mouse CYP1A1 mediates the 
production of vasodilatory products from EPA and DHA in vivo. 
Our data also suggest that the attenuation of vasodilation to EPA and DHA in 
arteries of CYP1A1 KO mice is not likely a result of altered downstream signaling.  There 
are no differences in the vasodilation responses between CYP1A1 WT and KO mice when 
the two putative CYP1A1-metabolites, 17,18-EEQ and 19,20-EDP, are applied directly to 
the arteries.  Further, DHA-mediated vasodilation is attenuated by two potassium channel 
inhibitors in both genotypes, again suggesting that downstream signaling that results in 
vasodilation is not different between genotypes. 
Irrespective of the P450 involved, our data also confirm that 17,18-EEQ and 
19,20-EDP are potent and efficacious vasodilators.  We found that 17,18-EEQ and 19,20-
EDP induce ~50% relaxation of the aorta at sub-nM concentrations and >90% relaxation 
at nM concentrations.  In general, the mesenteric arterioles are less responsive and require 
nM to M concentrations to induce vasodilation.  The potency and efficacy of 17,18-EEQ 
and 19,20-EDP in vasorelaxation of the mouse aorta is similar to the vasodilatory 
responses observed in porcine coronary microvessels (Zhang et al., 2001; Ye et al., 2002).  
However, the vasodilation responses to 17,18-EEQ in the mouse mesenteric arterioles is 
more similar to that observed in human pulmonary arteries with ~ 80% relaxation 
occurring at µM concentrations (Morin et al., 2009).  Thus, the vasodilatory responses to 
these n-3 PUFA metabolites are likely to be both species- and vascular bed-specific. 
Studies suggest that there are various downstream mechanisms by which EPA and 
DHA mediate their vasodilatory responses.  Wang et al. (2011) showed that the 
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vasodilatory actions of DHA are mediated by P450 metabolism and downstream activation 
of Kv and BK channels in rat coronary arteries, while Lauterback et al. (2002) showed 
that 17,18-EEQ hyperpolarizes vascular smooth muscles from rat cerebral arteries 
exclusively by BK channel activation.  Our data show blockade of BK channels alone does 
not attenuate DHA-mediated dilation in mouse mesenteric arteries; however, the 
simultaneous inhibition of Kv channels does significantly attenuate the dilation response, 
suggesting that BK channels may not play a role in DHA dilation in this microvascular 
bed.   
Finally, CYP1A1 KO mice exhibit key phenotypic characteristics that are distinct 
from age-matched CYP1A1 WT mice.  Body weights in CYP1A1 KO mice are 
significantly lower as are kidney and liver weights when normalized to body weight.  The 
decrease in liver weight is similar to the AHR KO mice which exhibit decreased liver size 
resulting from a persistent ductus venosus and reduced hepatocyte size (Lahvis et al., 
2000; Lahvis et al., 2005).  Further studies are needed to determine the underlying reasons 
for the differences in body and organ weights between CYP1A1 WT and KO mice.  Since 
the WT and KO mice used in this study are not littermates, it is possible that maternal 
factors could contribute to these differences.  
In summary, our study suggests for the first time that constitutive CYP1A1 
expression has a physiologically important role in the regulation of vascular function and 
blood pressure, which may involve vasodilatory responses to n-3 PUFAs.  Since CYP1A1 
is constitutively expressed in the vascular endothelium and physiological levels of shear 
stress can induce its expression, CYP1A1 metabolism of n-3 PUFAs could represent a 
novel pathway contributing to an anti-atherogenic phenotype.  Future studies will need to 
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determine whether the loss of n-3 PUFA vasodilation and potential increase in peripheral 
vascular resistance are the proximal mediators of the increase in blood pressure in 
CYP1A1 KO mice. 
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IV. CHAPTER 4 
Cytochrome P4501A1 contributes to nitric oxide-dependent vasodilation and blood 
pressure lowering on an omega-3 polyunsaturated fatty acid-enriched diet. 
In preparation for submission to Hypertension. 
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A. ABSTRACT 
Elevated blood pressure (BP) in cytochrome P4501A1 knockout (CYP1A1 KO) 
mice is associated with attenuated vasodilation to omega-3 polyunsaturated fatty acids (n-
3 PUFAs); eicosapentaenoic acids (EPA) and docosahexaenoic acids (DHA) ex vivo.  We 
tested the hypothesis that dietary supplementation of n-3 PUFAs rather than n-6 PUFAs 
will reduce BP in CYP1A1 KO mice via a nitric oxide synthase (NOS) dependent 
pathway.  Diets enriched in n-3 or n-6 PUFAs were fed to CYP1A1 WT and KO mice for 
2 months.  BP and heart rate (HR) was assessed by radiotelemetry in CYP1A1 WT and 
KO mice ± NOS inhibitor (N
ω
-nitro-L-arginine, LNNA), and following an acute Ang II 
challenge in vivo (30 µg/kg).  We measured endothelial NOS (eNOS) and phospho-eNOS 
protein expression in aorta, and also assessed mesenteric dose-responses to acetylcholine 
(ACh), and to the thromboxane A2 mimetic, U46619.  We found that an n-3 PUFA-
enriched diet significantly reduced mean arterial pressure (MAP) in CYP1A1 KO mice 
(Chow, 116.0 ± 1.2, n-3: 107.6 ± 1.5, p<0.005), with no effect in CYP1A1 WT mice 
(Chow, 103.0 ± 0.9, n-3: 105.0 ± 2.5).  In contrast, MAP in CYP1A1 WT mice fed an n-6 
PUFA-enriched diet was significantly increased (Chow, 103.0 ± 0.9, n-6: 118.2 ± 4.1, 
p<0.005), with no effect in CYP1A1 KO mice (Chow, 116.0 ± 1.2, n-6: 115.3 ± 1.5).  
Interestingly, NOS inhibition increased BP significantly more in the CYP1A1 WT mice 
(+16 ± 0.5 mmHg) than CYP1A1 KO mice (+11 ± 0.6, p<0.002) on an n-3 PUFA-
enriched diet, but resulted in similar increases in BP in CYP1A1 WT and KO mice on an 
n-6 PUFA-enriched diet (WT: +11 ± 1.8; KO: +11 ± 0.8).  Area under the curve analysis 
showed that Ang II significantly increased systolic BP in CYP1A1 KO mice fed an n-3 
PUFA-enriched diet, compared to CYP1A1 WT mice (WTn-3, 938 ± 90; KOn-3, 1250 ± 51, 
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p<0.05).  Additionally, CYP1A1KO mice on an n-3 PUFA-enriched diet exhibited 
significantly attenuated ACh-dependent vasodilation in mesenteric arterioles, and reduced 
expression of aortic phospho-eNOS protein, compared to CYP1A1 WT mice.  However, 
neither of the endpoints was altered in CYP1A1 KO mice on an n-6 diet, compared to 
CYP1A1 WT mice.  Taken together, these data suggest that CYP1A1 contributes to NO-
mediated vasodilation and BP lowering benefits derived from dietary n-3 PUFAs. 
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B. INTRODUCTION 
Although cardiovascular (CV) disease is a leading cause of death in the developed 
countries, studies have shown that there are considerable differences in the incidence and 
death rates among different cultures.  One of the contributing factors is dietary patterns, 
and numerous studies have shown that diets high in marine fish and mammals, which 
contain high levels of omega-3 polyunsaturated fatty acids (n-3 PUFAs), are inversely 
correlated with CV mortality.  For example, Greenland Eskimos, who consume diets 
highly enriched in n-3 PUFAs, show significantly lower rates of coronary heart disease and 
CV mortality than Western European countries  (Bang et al., 1980; Kromann and Green, 
1980).  These benefits are observed even among Western countries.  The Seven Countries 
Study of dietary eating patterns of more than 12,000 men shows that consumption of a 
diet high in fish significantly reduces the risk of death from acute myocardial infarction 
(Menotti et al., 1999).  The CV benefits of n-3PUFAs have been further confirmed by 
clinical trials.  Randomized human clinical trials show that n-3 PUFAs reduce the risk of 
cardiovascular death, myocardial infarction, and stroke by up to 20% (Marchioli et al., 
2002; Yokoyama et al., 2007).   
The mechanisms by which n-3 PUFAs mediate their cardioprotective benefits are 
multifactorial and include anti-hypertensive, anti-hyperlipidemic, anti-arrhythmic, and anti-
inflammatory effects.  For example, a meta-analysis of randomized human clinical trials 
found that n-3 PUFAs systematically reduce systolic and diastolic blood pressure (BP) 
(Morris et al., 1993; Geleijnse et al., 2002).  Additionally, n-3 PUFAs have been shown to  
significantly reduce triglyceride levels by up to 30% (Harris, 1997) and reduce plasma 
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levels of soluble adhesion molecules associated with the inflammatory disease process as 
shown in a meta-analysis of 18 separate studies (Yang et al., 2012).  
The mechanisms that mediate the anti-hypertensive effects of n-3 PUFAs have not 
been fully elucidated, but likely result from pro-vasodilatory effects.  n-3 PUFAs are 
metabolized to vasodilatory products via  cytochrome P450s (Schwarz et al., 2004; 
Schwarz et al., 2005; Fer et al., 2008; Lucas et al., 2010) and lead to  increases in nitric 
oxide (NO) bioavailability, a potent vasodilator (Rees et al., 1989).  Using a broad 
spectrum P450 inhibitor in rat coronary arteries, Wang et al., (2011) show that the 
vasodilatory actions of docosapentaenoic acid (DHA), an n-3 PUFA, require P450 
metabolism.  Further, multiple studies show that n-3 PUFAs increase the activation of 
endothelial nitric oxide synthase (eNOS) in cultured endothelial cells (Omura et al., 2001; 
Gousset-Dupont et al., 2007; Li et al., 2007a; Stebbins et al., 2008) and increase eNOS 
and NO production in rats and mice in vivo (Nishimura et al., 2000; Lopez et al., 2004; 
Ma et al., 2004).  Lastly, dietary n-3 PUFA supplementation in humans enhances NO-
dependent forearm vasodilation (Tagawa et al., 1999).  Nonetheless, it is not clear if 
P450-generated metabolites are responsible for the increases in NO production or if the 
increases in NO result from an independent mechanism. 
n-3 PUFAs are efficient and, in some cases, the preferred endogenous substrates 
for members of the CYP1A, CYP2D and CYP2E families of P450s,which metabolize n-3 
PUFAs in a stereospecific manner, generating potent and efficacious vasodilators 
(Barbosa-Sicard et al., 2005; Muller et al., 2007; Westphal et al., 2011).  For example, 
CYP1A1 metabolizes the principal n-3 PUFAs, DHA and eicosapentaenoic acids (EPA), 
to the stereospecific products 19(R),20(S)-epoxydocosapentaenoic acid (19(R),20(S)-
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EDP) and 17(R),18(S)-epoxyeicosatetraenoic acid (17(R),18(S)-EEQ), respectively 
(Schwarz et al., 2004; Lucas et al., 2010).  Both of these metabolites are potent 
vasodilators in microcirculatory vessels (Zhang et al., 2001; Morin et al., 2009).  Despite 
the knowledge of P450 metabolism of n-3 PUFAs, the contributions of individual P450s 
to the regulation of vascular tone and BP in vivo remains uninvestigated.  Recently, 
however, we demonstrate, using CYP1A1 knockout (KO) mice, that  CYP1A1 is a partial 
contributor  to the vasodilation responses to DHA and EPA and is required for regulating  
BP in vivo as CYP1A1 KO mice exhibit significant increases in BP, particularly when 
active (Agbor et al., unpublished data).  Nonetheless, these results show that CYP1A1 is 
not the sole mediator of the responses to n-3 PUFAs.  Since other P450s also efficiently 
metabolize n-3 PUFAs, we hypothesized that providing an n-3 PUFA-enriched diet to 
enhance substrate availability would reduce BP in CYP1A1 KO mice and this decrease 
would be mediated, in part, by increased NO bioavailability.  We further hypothesized that 
providing an n-6 PUFA-enriched diet to diminish n-3 PUFA substrate bioavailability 
would increase BP in CYP1A1 WT mice. 
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C. METHODS 
 
Chemicals 
Acetylcholine (ACh), N
ω
-nitro-L-arginine (LNNA), angiotensin (Ang) II, all 
ingredients of physiological saline solution (PSS) and HEPES-PSS were purchased from 
Sigma–Aldrich (St. Louis, MO).  U46619 was purchased from Cayman Chemical (Ann 
Arbor, MI). 
Animals 
CYP1A1 KO mice, backcrossed more than eight generations onto the C57BL/6J 
background, were generously provided by Dr.  Daniel Nebert (University of Cincinnati) 
and were bred at the University of New Mexico (Dalton et al., 2000).  Age-matched 
C57BL/6J mice served as wildtype (WT) controls.  All animals were housed in a 
temperature-controlled environment.  All animal protocols were approved by the 
University of New Mexico Animal Care and Use Committee and the investigations 
conform to the Guide for the Care and Use of Laboratory Animals published by the U. S. 
National Institutes of Health (NIH Publication No.  85-23, revised 1996).  When tissues 
were harvested and organ weight determined, mice were anesthetized with ketamine (80 
mg/kg)/xylazine (4 mg/kg).  The heart was removed, atria were dissected, and the total 
ventricle weight measured.  Kidneys and liver weights were also measured.  All tissues 
were frozen at −80°C.  
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Diets 
Mice were fed a standard chow rodent diet (product no. 2020XC, Teklad Diets, 
Harlan Laboratories, Madison WI), an n-3 PUFA-enriched diet containing 15% fish oil 
(wt/wt), or an n-6 PUFA-enriched diet containing 15% safflower oil/linoleic (wt/wt) 
(Teklad Diets, Harlan Laboratories) (Table 4.1).  Both PUFA diets were equivalent in 
total protein, carbohydrates, fat content and all other dietary components.  Diets were 
prepared in bulk, and packaged into individual 4 kg whirl-Pak bags (Nasco, Fort Atkinson, 
WI), flushed with nitrogen to minimize oxidation and stored at 4 °C.  Fresh diets were fed 
twice weekly.  Diets were weighed before and after administration to determine the 
amount of food consumed, and any uneaten food was discarded. 
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Table 4.1. Diet composition: Standard chow, n-3 PUFA enriched diet, and n-6 PUFA-enriched 
diet 
 
 
Composition 
Standard Chow 
(2020X) 
(% by weight) 
n-3 PUFA diet 
(TD.110516) 
(% by weight) 
n-6 PUFA diet 
(TD.110517) 
(% by weight) 
    
Protein 24.0 18.6 18.6 
Carbohydrates 60.0 52.2 52.2 
Total fat 16.0 15.2 15.2 
Kcal/g 3.1 4.2 4.2 
    
 
Fatty acids 
   
 
n-3 PUFA 
 
10 
 
80 
 
0 
n-6 PUFA 90 20 100 
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Blood pressure analysis 
 
Arterial BP and heart rate (HR) were measured using radiotelemetry in 4-5 month-
old CYP1A1 WT and KO mice (Data Sciences International, St. Paul, MN, USA) as 
previously described (Lund et al., 2008), using PA-C10 radiotelemeters.  Mice were 
allowed to recover from surgery for 7 d prior to data collection.  Basal BP, including 
systolic, diastolic, mean and pulse arterial BP, and HR were collected for 7 d before drug 
treatments began.  BP was recorded for 10 s every 15 min during baseline measurements.  
After basal BP was measured, all mice were treated with LNNA in the drinking water 
(250 mg/L) for one week followed by one week of washout (Duling et al., 2006).  In 
addition, BP was also measured for 10 s every 1 min for 30 min, starting 5 min following 
an acute Ang II injection (30 µg/kg i.p.).   
 
Mesenteric arteriole reactivity 
Mice were administered heparin (10 µl/g of 1000 units/ml) by intraperitoneal 
injection for 5 min, anesthetized with ketamine (80 mg/kg)/xylazine (4 mg/kg), and 
euthanized by exsanguination.  The intestine together with mesenteric arteries were 
quickly excised and placed in HEPES-PSS solution (134 mM NaCl, 6.0 mM KCl, 1 mM 
MgCl2, 2 mM CaCl2, 10 mM HEPES, 0.026 mM EDTA, 10 mM glucose, and buffered to 
pH 7.4 with NaOH).  The tissue was then pinned to the bottom of a petri dish, and a long 
segment of a first-order branch of the mesenteric artery was cleared from surrounding 
adipose tissue and dissected.  The artery was transferred to the chamber of a pressure 
myograph system (DMT -110 systems, Danish Myo Technology, Ann Arbor, MI) for 
cannulation.  The chamber was filled with warm PSS at 37 
0
C bubbled with 21% O2, 6% 
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CO2, balanced N2 (130 mM NaCl, 4.7 mM KCl, 1.18 mM KH2PO4, 1.17 mM MgSO4, 
14.9 mM NaHCO3, 5.5 mM glucose, 26 µM CaNa2EDTA, and 1.8 mM CaCl2, pH 7.4).  
One end of the vessel was cannulated with the outflow pipette and tied securely with 10-0 
ethilon surgical silk thread.  The other end of the vessel was then cannulated with the 
inflow pipette.  The pressure was then increased by 10 mmHg increment every 5 mins to a 
maximum of 60 mmHg, and the artery allowed to equilibrate for 30 min.  After 
equilibration, baseline internal was measured using edge detection software (MyoView 
acquisition software, DMTVAS 6.2.0.59 Danish Myo Technology, Ann Arbor, MI).  
Viability of arteries was tested by constriction to 60 mM KCl and vessels that failed to 
constrict to 30% of baseline internal diameter were discarded.  After a PSS wash, the 
artery was allowed to return to baseline diameter and to rest for at least 15 min.  Arteries 
were then preconstricted to 45% of internal diameter with U46619, and a dose response 
to ACh (0.001–100 mM) was conducted. A concentration-response to U46619 (0.01-1 
µM) was also conducted.  All experiments were performed without luminal flow.  
 
Western blot 
Aortas were cleaned of connective tissue and adventitial fat, and then 
homogenized in RIPA buffer (Santa Cruz Biotechnology, Santa Cruz, CA).  The 
homogenate was frozen at -80 °C for 15 min, sonicated for 10 s and centrifuged at 15,000 
x g 4 °C for 10 min.  Protein concentration was measured using micro BCA protein assay 
kit (Thermo Scientific, Rockford, IL, USA).  A 20 µg aliquot of protein was mixed with 
6X loading buffer (100 mM pH6.8 Tris-HCl, 4% sodium dodecyl sulfate, 0.2% 
bromophenol blue, 20% glycerol, 200 mM dithiothreitol) and denatured at 95 °C for 10 
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min.  Denatured samples were subjected to electrophoresis on 10 % Tris-HCL 
polyacrylamide gel at 150 V for 1 hour in running buffer (25 mM Tris-base, 150 mM 
glycine, 0.1% sodium dodecyl sulfate) and separated proteins were transferred to 
polyvinylidene fluoride (PVDF) membrane (Bio-Rad Laboratories) at 100 V for 1 hour in 
cold transfer buffer (20 mM Tris-base, 150 mM glycine, 20% methanol).  The membrane 
was washed with Tris-buffered saline (TBST, 0.8% NaCl, 0.02% KCl, 0.3% Tris-base, 
0.05% Tween-20, pH7.4) and blocked for 1 hour in 5% nonfat dry milk in TBST.  The 
blocked membrane was incubated with mouse anti-eNOS antibody (1:2000, BD 
Transduction Laboratories, San Jose, CA) or mouse anti-phopho-eNOS antibody (1:2000, 
BD Transduction Laboratories) at 4 °C overnight, washed with TBST, and incubated with 
horseradish peroxidase (HRP) conjugated goat anti-mouse (Southern Biotech, 
Birmingham, AL) for 1 hour at room temperature.  The membrane was washed with 
TBST and developed for 2 min with 1 mL supersignal west femto maximum sensitivity 
substrate (Thermo Scientific) using a KODAK Image Station 4000MM digital imaging 
system (Perkin-Elmer).  The membrane was stripped (7 M guanidine hydrochloride, 
0.75% KCl, 0.38% glycine, 50 µM EDTA, 0.14% 2-mercaptoethanol, pH10), washed 
with TBST, reblocked, and incubated with mouse β-actin (Santa Cruz Biotechnology) 
overnight, washed with TBST, incubated with HRP-conjugated goat anti-mouse IgG 
(Southern Biotech), washed and developed as above.  Protein quantification was done 
using Image J software (National Institutes of Health, USA). 
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Lipid profile, plasma NOx, and thiobarbituric acid reactive substances (TBARS) 
analyses.  
 
To analyze lipid profile prior to and following treatment with n-3 and n-6 PUFA-
enriched diet, CYP1A1 WT and KO mice were fasted for 12 h overnight and using whole 
blood, lipid panel analysis was conducted using lipid panel screening strips, with a 
CardioCheck PA analyzer (Polymer Technology Systems, Inc, CardioChek, Indiana, 
USA).  Total cholesterol, high density lipoprotein (HDL) cholesterol, and triglycerides 
were measured.  Further, mice were anesthetized with ketamine (80 mg/kg)/xylazine (4 
mg/kg) and euthanized by exsanguination.  Plasma was collected from whole blood using 
heparinized syringes and NOx levels were measured using the Griess colorimetric assay 
(Cayman Chemical).  Hearts were suspended in 1:10 weight:volume of saline, 
homogenized, and sonicated for 15 s at 40 V.  TBARS was measured in heart 
homogenates using an assay kit (OXItek, ZeptoMetric Corp, Buffalo, NY).  Triplicate 
samples were read on a spectrophotometer (Beckman Instruments DU Series 600), using 
a malondialdehyde (MDA) standard curve, and results expressed as MDA equivalents.    
 
Statistical analysis 
Diets- and genotype-related changes in organ and body weights were analyzed by 
two-way analysis of variance (ANOVA) with post hoc Holm-Sidak comparisons. 
Vasoreactivity and BP measurements following NOS inhibition and Ang II treatment were 
analyzed by repeated measures, two-way analysis of variance with post hoc Holm-Sidak 
comparisons. The eNOS and phospho-eNOS protein quantifications were analyzed using 
Student’s t-test. *p < 0.05 was considered statistically significant.
116 
 
D.        RESULTS 
Food consumption, body and organ weights, and lipid profile 
We measured food intake, and compared body and organ weights of CYP1A1 WT 
and KO mice fed an n-3 or n-6 PUFA-enriched diet at 8 months of age.  Regardless of 
genotype or diet, food intake was not different between treatment groups (Fig. 4.1).  Body 
and organs weights from CYP1A1 KO mice fed an n-3 PUFA-enriched diet were not 
different, compared to WT mice.  In contrast, CYP1A1 KO mice fed an n-6 PUFA-
enriched diet exhibited significantly lower body, heart and liver weights, compared to age-
matched CYP1A1 WT mice.  However, when heart and liver weights were normalized to 
body weight, there was no difference between CYP1A1 WT and KO mice (Table 4.2).  In 
addition, neither the n-3 nor n-6 PUFA-enriched diet had any effect on cholesterol levels, 
but both diets significantly reduced triglyceride levels in CYP1A1 KO and WT mice 
(Table 4.3). 
 
Effects of n-3 and n-6 PUFA-enriched diets on mean 24 hr BP and HR in CYP1A1 WT 
and KO mice  
Since n-3 PUFAs have anti-hypertensive effects due, in part, to their metabolism 
by P450s including CYP1A1, we sought to determine how diets enriched in n-3 PUFAs 
versus n-6 PUFAs would affect BP in CYP1A1 WT and KO mice.  BP of CYP1A1 WT 
and KO mice were measured by radiotelemetry.  CYP1A1 KO mice on standard chow 
exhibited elevated BP, compared to WT mice (mean arterial pressure (MAP) in mmHg, 
WTchow 103 ± 1, CYP1A1 KOchow 116 ± 1; p<0.05) (Fig. 4.2A).  An n-3 PUFA-enriched 
diet significantly reduced MAP in CYP1A1 KO mice, compared to KO mice on standard 
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chow (MAP in mmHg, CYP1A1 KOn-3, 107.6 ± 1.5; p<0.05), but had no affect on MAP 
in  CYP1A1 WT mice (CYP1A1 WTn-3: 105.0 ± 2.5), (Fig. 4.2B).  In contrast, an n-6 
PUFA-enriched diet significantly increased MAP in CYP1A1 WT mice, compared to WT 
mice on standard chow (WTn-6 118.2 ± 4.1; p<0.05), but had no affect on MAP in 
CYP1A1 KO mice (CYP1A1 KOn-6 115.3 ± 1.5) (Fig. 4.2C).  HR increased in CYP1A1 
KO mice fed an n-3 PUFA-enriched diet, but there were no other differences in HR among 
groups (Fig. 4.2D). 
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Figure 4.1. Food consumption in CYP1A1 WT and KO mice fed an n-3 PUFA-enriched 
diet or n-6 PUFA-enriched diet.  Data represent mean ± SEM and were analyzed by 
student t-test (n=8/genotype/diet). 
 
119 
 
 
Table 4.2. Body and organ weights in 8 month-old CYP1A1 WT and KO mice on n-3 and 
n-6 PUFA-enriched diets 
 
 
Values are expressed as mean ± SEM 
*p < 0.05 versus corresponding WT 
 †
(Organ/body weight ratio x 100) 
 
Weight CYP1A1  
WT n-3 
(n=8) 
CYP1A1  
KO n-3 
(n=8) 
CYP1A1  
WT n-6 
(n=8) 
CYP1A1  
KO n-6 
(n=8) 
Body (g) 
 
32.5 ± 1.1 31.2 ± 0.9 31.9 ± 0.8 28.2 ± 1.0* 
Heart (mg) 128 ± 4 
(0. 397 ± 0. 
256)
†
 
120 ± 4 
(0. 387 ± 0. 
244) 
122 ± 2 
(0. 386 ± 0. 
179) 
110 ± 0.9* 
(0. 394 ± 0. 
160) 
Liver (mg) 1661 ± 95 
(5.0 ± 0. 173) 
1553 ± 43 
(5.0 ± 0. 190) 
1382 ± 27 
(4.3 ± 0. 128) 
1245 ± 37* 
(4.4 ± 0. 064) 
Kidney (mg) 403 ± 13 
(1.2 ± 0. 075) 
369 ± 13 
(1.2 ± 0. 076) 
329 ± 7 
(1.0 ± 0. 046) 
348 ± 9 
(1.2 ± 0. 035) 
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Table 4.3. Lipid profile measurements in CYP1A1 WT and KO mice fed standard chow, 
an n-3 and an n-6 PUFA-enriched diet 
 
 
Parameters CYP1A1 
WT chow 
(n=7) 
CYP1A1 
KO chow 
(n=7) 
CYP1A1 
WT n-3 
(n=3) 
CYP1A1 
KO n-3 
(n=4) 
CYP1A1 
WT n-6 
(n=4) 
CYP1A1 
KO n-6 
(n=3) 
 
Total 
cholesterol 
(mg/dL) 
 
 
<100 
 
<100 
 
<100 
 
<100 
 
<100 
 
<100 
HDL 
cholesterol 
(mg/dL) 
 
76 ± 5 
 
87 ± 6 
 
34 ± 5* 
 
37 ± 2* 
 
75 ± 5 
 
84 ± 9 
 
Triglycerides 
(mg/dL) 
95 ± 22 
 
83 ± 23 
 
<50 
 
<50 
 
<50 
 
<50 
 
 
 
Values are expressed as mean ± SEM 
*p < 0.05, vs chow and n-6 diet 
Legend: KO, CYP1A1 KO; WT, Wildtype. 
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Figure 4.2. Effects of n-3 and n-6 PUFA-enriched diets on mean 24 hr BP and HR in 
CYP1A1 WT and KO mice.  (A) MAP in CYP1A1 WT and KO mice fed standard chow, 
(B) an n-3 PUFA-enriched diet or (C) an n-6 PUFA-enriched diet.  (D) Corresponding HR 
of CYP1A1 WT and KO mice fed standard chow, an n-3 PUFA-enriched diet, or an n-6 
PUFA-enriched diet.  Data represent mean ± SEM and were analyzed by Student’s t-test.  
Bars with the same letters are not different from each other. *p < 0.05 
(n=7/genotype/diet). 
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Effects of an n-3 PUFA-enriched diet ± LNNA on mean hourly BP and HR in CYP1A1 
WT and KO mice. 
To determine the contribution of NO to the reduction in BP in CYP1A1 KO mice 
fed an n-3 PUFA-enriched diet, we treated CYP1A1 WT and KO mice with the NOS 
inhibitor, LNNA for 1 week and continuously assessed changes in BP and HR by 
radiotelemetry.  Hourly MAP over a 24 hr period prior to LNNA treatment was 
comparable between CYP1A1 WT and KO mice on an n-3 PUFA-enriched diet (Fig. 
4.3A).  Following NOS inhibition, hourly MAP increased in both CYP1A1 WT and KO 
mice, but it increased significantly less in CYP1A1 KO mice especially during nighttime 
periods of increased activity, although the normal circadian pattern of an increased MAP 
during the night wakeful period was preserved (Fig. 4.3B).  Although the 24 hr mean HR 
was not significantly different between CYP1A1 WT and CYP1A1 KO mice fed an n-3 
PUFA-enriched diet, when hourly HR was compared over a 24 hr period, CYP1A1 KO 
mice exhibited significantly lower HR at multiple times, particularly during peak activity 
after lights were turned off, compared to WT mice (Fig. 4.3C).  Following NOS inhibition, 
HR decreased in both genotypes, but again CYP1A1 KO mice exhibited a lower HR 
particularly when active, compared to WT mice (Fig. 4.3D).  Further, the increase in MAP 
following NOS inhibition was significantly greater in CYP1A1 WT mice (+16 ± 0.5 
mmHg) than KO mice (+11 ± 0.6, p<0.002), (Fig. 4.3E).  However, the decrease in HR 
following NOS inhibition was not different between treatment groups (Fig. 4.3F).  
Additionally, following NOS inhibition in CYP1A1 WT and KO mice on both standard 
chow and n-3 PUFA-enriched diets, BP increased significantly more in WT mice on an n-3 
PUFA-enriched diet (Fig. 4.4). 
123 
 
 
 
Figure 4.3. Effects of an n-3PUFA-enriched diet ± LNNA on mean hourly BP and HR in 
CYP1A1 WT and KO mice.  (A) Hourly MAP over a 24 hr period , (B) Hourly MAP over 
a 24 hr period after NOS inhibition by LNNA, (C) Hourly HR and (D) Hourly HR after 
NOS inhibition by LNNA. (E) Change in MAP and (F) Change in HR following NOS 
inhibition.  Data represent mean ± SEM and were analyzed by two-way, repeated 
measures ANOVA, using post hoc Holm-Sidak comparisons; *p < 0.05, compared to 
corresponding CYP1A1 WT (A-D), and by Student’s t-test (E and F) (n=4-7/genotype). 
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Figure 4.4. Effects of NOS inhibition on MAP in CYP1A1 WT and KO mice fed standard 
chow and an n-3 PUFA-enriched diet.  Change in MAP following NOS inhibition by 
LNNA.  Data represent mean ± SEM and were analyzed by two-way ANOVA, using post 
hoc Holm-Sidak comparisons; *p < 0.05 (n=4-7/genotype). 
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Effects of an n-6 PUFA-enriched diet ± LNNA on mean hourly BP and HR in CYP1A1 
WT and KO mice  
To determine if a loss of NO contributed to the increase in BP in CYP1A1 WT 
mice fed an n-6 PUFA-enriched diet, we treated CYP1A1 WT and KO mice with the NOS 
inhibitor, LNNA as described above.  Hourly MAP over a 24 hr period prior to LNNA 
treatment was comparable between CYP1A1 WT and KO mice (Fig. 4.5A).  Following 
NOS inhibition, hourly MAP increased, but remained similar between genotypes (Fig. 
4.5B).  Additionally, hourly HR over a 24 hr period was similar between genotypes both 
before (Fig. 4.5C) and after NOS inhibition (Fig. 4.5D).  Finally, the increase in MAP 
(Fig. 4.5E) and decrease in HR (Fig. 4.5F) following NOS inhibition did not differ 
between genotypes. 
 
Effects of n-3 PUFA-enriched diet on acute Ang II responsiveness in CYP1A1 WT and 
KO mice in vivo. 
To determine if the CYP1A1 KO mice fed an n-3 PUFA-enriched exhibited an 
enhanced response to vasoconstriction, we challenged CYP1A1 WT and KO mice with a 
bolus dose of Ang II (30 µg/kg) and recorded BP starting 5 min after i.p. injection.  An 
immediate, robust increase in BP following Ang II injection was observed in both 
genotypes; however, the increase in systolic BP was significantly greater in CYP1A1 KO 
mice, compared to WT mice, during the first 5 minutes following Ang II administration as 
well as from 10-15 min and 20-30 min post injection (Fig. 4.6A).  Area under the curve 
analysis following Ang II injection showed that systolic BP was significantly increased in 
CYP1A1 KO mice (WT, 938 ± 90; KO, 1250 ± 51, p<0.05) (Fig. 4.6B).   
126 
 
 
 
Figure 4.5. Effects of an n-6 PUFA-enriched diet ± LNNA on mean hourly BP and HR in 
CYP1A1 WT and KO mice.  (A) Hourly MAP over a 24 hr period , (B) Hourly MAP over 
a 24 hr period after NOS inhibition by LNNA, (C) Hourly HR, and (D) Hourly HR after 
NOS inhibition by LNNA. (E) Change in MAP and (F) Change in HR following NOS 
inhibition.  Data represent mean ± SEM and were analyzed by two-way, repeated 
measures ANOVA, using post hoc Holm-Sidak comparisons; *p < 0.05, compared to 
corresponding CYP1A1 WT (A-D), and by Student’s t-test (E and F) (n=4-7/genotype). 
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Figure 4.6.  Effects of n-3 PUFA-enriched diet on acute Ang II responsiveness in 
CYP1A1 WT and KO mice in vivo.  (A) Increase in systolic BP (SBP) and (B) Area under 
the curve analysis for 30 min following i.p. injection of Ang II (30 µg/kg).  BP was 
recorded starting after 5 mins of Ang II administration.  Data represent mean ± SEM and 
were analyzed by two-way, repeated measures ANOVA, using post hoc Holm-Sidak 
comparisons; *p < 0.05 compared to CYP1A1 WT (A).  Data in (B) were analyzed by 
Student’s t-test. (n=4/genotype). 
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Effects of n-3 and n-6 PUFA-enriched diets on aortic eNOS and phospho-eNOS protein 
expression in CYP1A1 WT and KO mice 
To further elucidate the potential contribution of NOS to differences in BP, we 
measured protein expression of eNOS and phospho-eNOS from aortas of CYP1A1 WT 
and KO mice fed an n-3 or an n-6 PUFA-enriched diet.  We found that eNOS protein 
expression in the aorta was not different between CYP1A1 WT and KO mice between 
diets (Fig. 4.7A-D).  In contrast, phospho-eNOS protein expression was significantly 
reduced in CYP1A1 KO mice fed an n-3 PUFA-enriched diet, compared to WT mice (Fig. 
4.8A and B).  There was no difference in phospho-eNOS expression between CYP1A1 
WT and KO mice fed an n-6 PUFA-enriched diet (data not shown).  
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Figure 4.7. Effects of n-3 and n-6 PUFA-enriched diets on aortic eNOS protein 
expression in CYP1A1 WT and KO mice.  Aortic eNOS protein expression and 
quantification relative to β-actin in CYP1A1 WT and KO mice fed an n-3 PUFA-enriched 
diet (A and B), or an n-6 PUFA-enriched diet (C and D).  Data represent mean ± SEM 
and were analyzed by Student’s t-test; *p < 0.05, compared to corresponding WT (n=3-
4/genotype/diet) 
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Figure 4.8. Effects of an n-3 PUFA-enriched diet on aortic phospho-eNOS protein 
expression in CYP1A1 WT and KO mice.  (A) Aortic p-eNOS and β-actin protein 
expression, (B) Quantification of p-eNOS protein expression relative to β-actin in 
CYP1A1 WT and KO mice fed an n-3 PUFA-enriched diet.  Data represent mean ± SEM 
and were analyzed by Student’s t-test; *p < 0.05, compared to WT.  (n=3-4/genotype) 
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Effects of n-3 and n-6 PUFA-enriched diets on ACh-mediated vasodilation, and U46619-
dependent vasoconstriction in mesenteric arterioles of CYP1A1 KO and WT mice 
To determine if vascular reactivity was altered in mice fed an n-3 or n-6 PUFA-
enriched diet, we assessed mesenteric arteriolar vasodilation to ACh and vasoconstriction 
to U46619.  We found that CYP1A1 KO mice on an n-3 PUFA-enriched diet exhibited an 
attenuated, dose-dependent vasodilation to ACh, compared to WT mice (Fig. 4.9A).  In 
contrast, there was no difference in ACh-mediated vasodilation between CYP1A1 WT and 
KO mice on an n-6 PUFA-enriched diet (Fig. 4.9B).  Further, dose-dependent 
vasoconstriction to U46619 did not differ between genotypes on either diet (Fig. 4.9C and 
D).   
 
Effects of n-3 and n-6 PUFA-enriched diets on plasma NOx levels  
To determine if CYP1A1 WT and KO mice exhibited differences in systemic levels 
of NO, we measured plasma NOx.  We found that plasma NOx levels were not different 
between CYP1A1 WT and KO mice on neither an n-3 PUFA-enriched diet nor an n-6 
PUFA-enriched diet (Fig. 4.10).  
 
Effects of standard chow, n-3 and n-6 PUFA-enriched diets on cardiac TBARS levels  
To determine the effects of the different diets on tissue oxidative stress levels, we 
measured cardiac TBARS.  Levels of cardiac TBARS were significantly elevated in 
CYP1A1 WT and KO mice on an n-3 PUFA-enriched diet, compared to mice on standard 
chow or an n-6 PUFA-enriched diet (Fig. 4.11).  Nonetheless, the effects of the different 
diets on TBARS levels were independent of genotype.  
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Figure 4.9. Effects of n-3 and n-6 PUFA-enriched diets on ACh-mediated vasodilation 
and U46619-dependent vasoconstriction in mesenteric arterioles of CYP1A1 WT and KO 
mice.  (A) ACh-mediated relaxation in mesenteric arterioles of CYP1A1 WT and KO mice 
fed an n-3 PUFA-enriched diet or (B) an n-6 PUFA-enriched diet.  (C) U46619-mediated 
vasoconstriction in mesenteric arterioles of CYP1A1 WT and KO mice fed an n-3 PUFA-
enriched diet or (D) an n-6 PUFA-enriched diet.  Data represent mean ± SEM and were 
analyzed by two-way, repeated measures ANOVA, using post hoc Holm-Sidak 
comparisons; *p < 0.05, compared to corresponding WT (n=8/genotype/diet). 
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Figure 4.10.  Effects of n-3 and n-6 PUFA-enriched diets on plasma NOx  levels.  Plasma 
NOx level in CYP1A1 WT and KO fed either an n-3 PUFA-enriched diet or an n-6 
PUFA-enriched diet.  Data represent mean ± SEM and were analyzed by Student’s t-test 
(n=5/genotype/diet).  
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Figure 4.11.  Effects of standard chow, n-3 PUFA-enriched diet, and n-6 PUFA-enriched 
diet on cardiac TBARS levels.  Cardiac TBARS levels in CYP1A1 WT and KO mice fed 
standard chow, an n-3 PUFA-enriched diet and an n-6 PUFA-enriched diet.  Data 
represent mean ± SEM and were analyzed by Student’s t-test.  Bars with the same letters 
are not different from each other. *p < 0.05 (n=5/genotype/diet). 
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E.        DISCUSSION 
These results show that an n-3 PUFA-enriched diet effectively reduces BP in 
CYP1A1 KO mice to CYP1A1 WT levels, demonstrating that CYP1A1 is not solely 
required to mediate the antihypertensive benefits of n-3 PUFAs.  Further, our results show 
that the benefits of the n-3 PUFA diet on BP result, in part, by increases in NO as is 
illustrated by the significantly greater increase in BP when WT mice are treated with a 
NOS inhibitor, compared to WT mice on standard chow or an n-6 PUFA diet.  
Interestingly, CYP1A1 is required to mediate the n-3 PUFA-dependent increase in NO, 
since BP does not increase to the same extent in CYP1A1 KO mice treated with a NOS 
inhibitor, compared to WT mice.  The contribution of CYP1A1 to n-3 PUFA-dependent 
increases in NO is further illustrated by the significantly reduced expression of phospho-
eNOS protein and the attenuation of ACh-mediated vasodilation in CYP1A1 KO mice, 
compared to WT mice on the n-3 PUFA diet.  Finally, our results show that BP and 
vascular reactivity of CYP1A1 WT and KO mice are essentially identical when fed an n-6 
PUFA-enriched diet, suggesting that CYP1A1 is not necessary for n-6 PUFA-dependent 
regulation of BP or vascular homeostasis 
Numerous studies demonstrate that an n-3 PUFA-enriched diet or n-3 PUFA 
supplements can lower BP in hypertensive laboratory animals and human subjects.  For 
example, an n-3 PUFA-enriched diet fed for two months decreases BP in aged male and 
female spontaneously hypertensive rats (Mitasikova et al., 2008; Dlugosova et al., 2009).  
Similarly, n-3 PUFAs significantly reduce hypertension in rats infused with Ang II (Hui et 
al., 1989).  Moreover, a meta-analysis of 31 placebo-controlled trials shows that n-3 
PUFAs significantly reduce BP in hypertensive humans and exhibit a dose-dependent 
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effect (Morris et al., 1993).  Our data showing that an n-3 PUFA-enriched diet fed for two 
months significantly reduces MAP in modestly hypertensive CYP1A1 KO mice is 
consistent with these previously published studies.  Further, our results show that 
CYP1A1 is not required to mediate this decrease.  In addition, we found that an n-3 
PUFA-enriched diet does not reduce MAP in normotensive C57BL/6J mice.  This is in 
contrast to a limited number of studies that show n-3 PUFAs also can reduce BP in 
normotensive animals and humans (Mori et al., 1999; Dlugosova et al., 2009; Liu et al., 
2011).  
One mechanism by which n-3 PUFAs may regulate vascular function and BP is 
thought to involve an increase in NO bioavailability and signaling.  In cultured HUVECs, 
n-3 PUFAs increase the translocation of eNOS from caveolin to the cytosol, a step 
required for activation (Omura et al., 2001; Li et al., 2007a; Li et al., 2007b) and 
subsequently lead to increases in NO production, while in EA hy 926 endothelial cells n-3 
PUFAs increase the expression of phospho-eNOS, the activated form of the enzyme 
(Gousset-Dupont et al., 2007).  Additionally, in vivo studies demonstrate that rats fed n-3 
PUFAs exhibit increases in aortic eNOS expression (Ma et al., 2004), activity (Dlugosova 
et al., 2009), and NO production (Lopez et al., 2004),  as well as improvements in NO-
dependent vasodilation (Matsumoto et al., 2009).  Finally, a meta-analysis of randomized 
controlled human trials shows that n-3 PUFA supplements significant improve NO-
dependent brachial artery vasodilation (Wang et al., 2012). 
Although CYP1A1 is not required to mediate the decrease in BP by the n-3 PUFA 
diet, a number of lines of evidence from our study suggest that CYP1A1 does mediate 
increases in NO bioavailability resulting from the n-3 PUFA diet.  We found that aortic 
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phospho-eNOS protein expression is significantly lower in CYP1A1 KO mice fed an n-3 
PUFA-enriched diet, compared to WT mice.  Further, ACh-mediated vasodilation is 
significantly attenuated in CYP1A1 KO mice fed an n-3 PUFA-enriched diet, compared to 
WT mice.  Finally, the increase in BP resulting from NOS inhibition is significantly less in 
CYP1A1 KO mice fed an n-3 PUFA-enriched diet, compared to WT mice.  These results 
suggest that CYP1A1 contributes to n-3 PUFA-dependent increases in NO.  The 
mechanism underlying these observations remains to be elucidated; however, limited 
evidence supports the notion that there may be cross-talk between caveolin-1, CYP1A1, 
and eNOS (Lim et al., 2007).  Nonetheless, since eNOS knockout mice are hypertensive 
(Shesely et al., 1996), it will be interesting to elucidate the contribution of n-3 PUFAs in 
reducing BP in the eNOS knockout mice, and the mechanisms involve.   
One particularly surprising observation is that the n-6 PUFA-enriched diet 
significantly increases BP in CYP1A1 WT mice, but has no effect in CYP1A1 KO mice, 
compared to these same mice fed a standard chow diet.    These results, however, are 
consistent with studies showing n-3 PUFA deficient diets lead to increases in BP.  Ren-2 
rats that have high levels of Ang II show significantly higher BP when maintained on an n-
3 PUFA deficient diet from conception (Jayasooriya et al., 2008).  Similarly, rats fed n-3 
PUFA deficient diets from the prenatal period through adulthood show significantly higher 
BP at 9 months of age (Begg et al., 2012).  While our n-6 PUFA-enriched diet did not 
contain any detectable amounts of n-3 PUFAs, we would not have expected that the two 
month duration of feeding was sufficiently long to deplete all endogenous n-3 PUFAs.  
Nonetheless, results of the tissue and blood analysis of PUFA and PUFA metabolites from 
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CYP1A1 WT and KO on each diet should help us to further interpret the changes in BP 
observed following the n-6 PUFA-enriched diet. 
Lastly, we also observed fundamental differences in body and organ weights in 
CYP1A1 WT and KO mice fed either an n-3 PUFA or n-6 PUFA-enriched diet.  We 
reported previously that CYP1A1 KO mice fed standard chow exhibit reduced body, 
heart, kidney and liver weights, compared to WT mice (Kopf et al., 2010)(Agbor at el., 
unpublish data).  Notably, however, our current findings show that body and organ 
weights of CYP1A1 KO mice are normalized by an n-3 PUFA-enriched diet, but not an n-
6 PUFA-enriched diet.  Rockett et al., (2010, 2012) report that high doses of n-3 PUFAs 
increase body weight and reduce activity of C57BL/6 mice.  Similarly, mice fed an n-3 
PUFA-enriched diet exhibited significant increase in body weight at 14 weeks, compared 
to control diet (Anderson et al., 2012).  Since CYP1A1 KO mice exhibit significantly 
lower activity on the n-3 PUFA-enriched diet (data not shown), compared to WT mice, 
this could account for the normalization of body and organ weights.  Nonetheless, 
additional studies assessing metabolic activity will be needed to determine if changes in 
physical activity are reflected by changes in metabolism. 
In summary, our study demonstrates that an n-3 PUFA-enriched diet increases the 
contribution of NO to vascular function and BP regulation, and this is mediated, in part, 
by CYP1A1.  Given that CYP1A1 is constitutively expressed in the vascular endothelium 
and is induced by physiological levels of shear stress (Han et al., 2008; Conway et al., 
2009), this pathway could provide some cardiovascular and BP-lowering benefits 
following dietary intake of foods enriched in n-3 PUFAs, in addition to regular exercise 
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regimens.  Future studies are however, needed to investigate crosstalk between CYP1A1 
and NOS signaling in contributing to the BP lowering effects of n-3 PUFAs. 
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V.        CHAPTER 5 
 
Conclusion and future directions 
 
I.           Endothelial cell-specific aryl hydrocarbon receptor knockout (ECahr
-/-
) mice 
and blood pressure (BP) regulation. 
Conclusion 
 
Our primary objective was to develop an endothelial cell-specific aryl hydrocarbon 
receptor (AHR) knockout (KO) (ECahr
-/-
) mouse to investigate the contribution of 
endothelial AHR to BP regulation.  We successfully generated ECahr
-/- 
mice with genetic 
deletion of the AHR in the endothelium using cre-lox recombination, and our data 
revealed that ECahr
-/-
 mice are hypotensive, similar to the BP phenotype of the AHR KO 
mice (Zhang et al., 2010).  This demonstrates that endothelial-expressed AHR is a critical 
regulator of vascular tone and BP.   
Hypotension in ECahr
-/-
 mice was associated with altered gene expression of tissue 
renin angiotensin system (RAS) components, as well as decreased protein expression of 
aortic angiotensin 1 receptor (AT1R).  In addition, the reduced BP was mediated, in part, 
by a reduced vasoconstriction response to Ang II, measured both in vivo and ex vivo in 
ECahr
-/-
 mice, compared to ECahr
-+/+
 mice.  Vasoreactivity studies in the aorta showed a 
significant reduction in vasoconstriction to Ang II in the ECahr
-/-
 mouse aorta in the 
presence of perivascular adipose tissue (PVAT).   Additionally, renin and AT1R mRNA 
expression were significantly reduced in the visceral white adipose tissue.  Nonetheless the 
specific mechanism through which the AHR regulates AT1R expression is still unclear and 
warrants further investigation.   
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Classically, the AHR modulates gene expression by binding to dioxin response 
elements (DRE) containing the core recognition motif 5’-TNGCGTG-3’ (Denison et al., 
1989).  Interestingly, several DRE sequences are located in the promoter region of both 
the mouse AT1a and AT1b genes, supporting the possibility that expression of the mouse 
AT1R in the vasculature could directly be modulated by the AHR.  Supporting evidence 
for this comes from studies where activation of the AHR by TCDD was demonstrated to 
sensitize mice to Ang II-mediated hypertension.  Taken together, this suggests that AHR 
expression in the endothelium is particularly important to normal vascular responsiveness 
to Ang II and thus, BP regulation.  
 
Future direction 
Although our findings establish an association between loss of endothelial AHR 
and reduced RAS signaling, it does not elucidate how the AHR regulates the AT1 
receptor.  Therefore, future studies should focus on determining the interaction between 
the AHR and the AT1 receptor.  One possible way to investigate this is in cell culture 
studies.  Using human umbilical vein endothelial cells, the AHR receptor could be knocked 
down by RNA interference.  AT1 mRNA and protein expression profiles from both siRNA 
treated and untreated cells would demonstrate whether the loss of AHR contributes to the 
downregulation and reduced expression of the AT1 receptor mRNA and protein.  If this is 
not the case, since the mRNA of AHR and its downstream target gene, CYP1A1, have 
been shown to be inducible in vsmc (Kerzee and Ramos, 2001), targeted knockdown of 
AHR could also be conducted in vsmc in culture.   
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The AHR activates its gene battery by binding to DREs in the promoters of genes 
to turn them on (Boutros et al., 2004; Tijet et al., 2006).  Interestingly, the AT1 receptor 
gene sequence harbors several DREs in its promoter; however, their transcriptional 
regulation by the AHR has not been demonstrated.  It is plausible therefore, that basal 
AHR levels could contribute to the expression of constitutive AT1 receptor by binding to 
DREs in its promoter region.  To investigate this, we could use a luciferase reporter 
plasmid system containing specific nucleotide deletions of the AT1 receptor promoter, and 
transfect into cell lines, for example HEK29 cell lines.  Following treatment with an AHR 
agonist such as dioxin, we could determine by luciferase activity measurements, if specific 
DNA regions of the AT1 receptor promoter region is regulated by the AHR.   
To further elucidate how the AHR could regulate the AT1 receptor, we could 
conditionally delete the AHR specifically from the vsmc in mouse, to determine if AHR in 
vsmc alters Ang II signaling and BP in vivo.  Notably, mice expressing cre-recombinase 
driven under a vsmc specific promoter, smooth muscle 22-alpha (SM-22α), could be bred 
to mice harboring exon 2 of the AHR gene flanked by lox-P sites.  Through two 
generation of breeding, mice that are cre-positive or negative but harbor the floxed AHR 
allele could be used as conditional knockouts and wildtype controls, respectively.  AT1R 
mRNA and protein levels in aorta and mesenteric arterioles could be determined.  In 
addition, BP could also be measured using radiotelemetry to demonstrate whether the loss 
of AHR only from the vsmc is involved in BP regulation.  If a significant reduction in BP 
is not seen, then an acute in vivo challenge to Ang II could be conducted to determine if a 
vascular deficit is present in the vasculature as a result of loss of AHR from vsmc.  
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In summary, the contributions of the endothelial AHR to BP regulation and the 
underlying mechanisms involved are not well understood.  Nonetheless, the findings from 
this study and those from the AHR KO mice suggests that there is significant cross talk 
between AHR signaling and the RAS and future studies delineating this interaction would 
be necessary.   
In conclusion, the results from the AHR KO and the ECahr
-/-
 mice show that both 
models are hypotensive, suggesting that global deletion of the AHR or loss of the AHR 
specifically from the vascular endothelium contributes to hypotension, in part, by 
significantly attenuating Ang II responses.  Taken into account that RAS is the primary 
contributor to the pathogenesis of hypertension, it is plausible that the AHR crosstalk with 
the RAS.  The implication therefore is that specific AHR antagonists could be designed 
and tested as potential anti-hypertensives in the treatment of high BP in humans, in 
combination with other anti-hypertensive agents including Ang converting enzyme 
inhibitors.  
 
II.         Cytochrome P4501A1 knockout (CYP1A1 KO) mice and BP regulation 
Conclusion 
 
The findings reported herein show that CYP1A1 KO mice exhibit elevated BP 
with a reduced HR.  Systolic BP was significantly elevated at nighttime periods of 
increased activity, while diastolic BP was significantly increased across 24 hr period, 
compared to WT mice.  Additionally, CYP1A1 KO mice exhibited attenuated vasodilation 
to DHA and EPA in the aorta and mesenteric arterioles, but normal responses to NOS 
inhibition and aortic vasorelaxation to ACh and SNAP, suggesting that elevated BP in 
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CYP1A1 KO mice is not associated with loss of NO.  Our data further demonstrate that 
putative CYP1A1 metabolites of EPA and DHA, 17,18-EEQ and 19,20-EDP, are potent 
and efficacious vasodilators.  Lastly, inhibition of Kv channel significantly inhibited DHA-
mediated vasodilation in mesenteric arterioles.  Our data suggests that the limiting factor 
could be the amount of vasodilator metabolites produced by CYP1A1 metabolism of n-3 
PUFAs.  Taken together, the findings from our study show for the first time that CYP1A1 
is required in maintaining normal levels of BP.  
In addition, diets enriched in n-3 PUFAs contributed significantly in lowering BP in 
CYP1A1 KO mice.  Notably, elevated BP in CYP1A1 KO mice was lowered to 
comparable WT levels after supplementing for 2 months with an n-3 PUFA-enriched diet, 
with no effects in CYP1A1 WT mice.  In contrast, BP in WT mice significantly increased 
after supplementing with an n-6 PUFA-enriched diet, with no effect in CYP1A1 KO mice.  
Phospho-eNOS protein expression was significantly reduced in the aorta of CYP1A1 KO 
mice fed an n-3 PUFA-enriched diet, compared to CYP1A1 WT mice.  Moreover, 
although BP was reduced in the CYP1A1 KO mice fed an n-3 PUFA-enriched diet, 
following NOS inhibition, BP increase was significantly less in CYP1A1 KO, compared to 
WT mice.  Additionally, ACh-mediated vasodilation was attenuated in mesenteric 
arterioles from CYP1A1 KO mice fed an n-3 PUFA-enriched diet, compared to WT mice, 
with no difference in mice on an n-6 PUFA-enriched diets.  Although we have previously 
reported that CYP1A1 KO mice exhibited reduced body and organ weights on standard 
chow (Kopf et al., 2010), our data herein show that body and organ weights of CYP1A1 
KO mice were normalized by an n-3 PUFA-enriched diet, but not on an n-6 PUFA-
enriched diet.  Consistent with studies demonstrating that n-3 PUFA supplementation 
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results in weight gain via reduced activity in mice (Anderson et al., 2012; Rockett et al., 
2012), average 24 hr and nighttime activity measurements were significantly reduced in 
CYP1A1 KO mice, compared to CYP1A1 WT mice on an n-3 PUFA-enriched diet. 
Taken together, our study suggests that the mechanism of action of n-3 and n-6 
PUFAs might be different.  As seen, the difference in BP phenotypes between n-3 and n-6 
PUFA-enriched diets demonstrate that both diets could have opposing effects in 
contributing to vascular tone and BP control, and involves CYP1A1.  Thus, increasing 
substrate availability via n-3 PUFA supplementation, changes the BP phenotype of 
CYP1A1 KO mice towards that of WT mice, and depleting substrate availability via n-6 
PUFA supplementation changes the BP phenotype of CYP1A1 WT mice to that of 
CYP1A1 KO mice. 
 
Future directions 
 
The phenotype of the CYP1A1 KO mouse provides a good model to further 
elucidate the physiological role of CYP1A1 in contributing to cardiovascular homeostasis.  
The hypertensive phenotype strongly suggests that CYP1A1 is involved in contributing to 
vascular tone and BP regulation.  Although CYP1A1 has been demonstrated to be induced 
by physiological levels of shear stress in vascular endothelial cells (Han et al., 2008; 
Conway et al., 2009), its beneficial role following shear-induction has not been elucidated.  
To initially investigate this, vascular endothelial cells from CYP1A1 WT and KO mice 
could be isolated and cultured.  Following NOS inhibition with LNNA (100 µM), 
endothelial cells could be subjected to laminar shear stress of 15-25 dynes/cm
2
, and the 
media collected and applied to pressurized mesenteric arterioles from C57BL/6J mice, 
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preconstricted to U46619.  Mesenteric vasodilation can be monitored and compared to 
media subjected to no shear stress.  Further, we could also investigate this in vivo using 
radiotelemetry to monitor BP.  Notably, in CYP1A1 WT and KO mice, following NOS 
inhibition, MAP could be measured prior to, during, and following an exercise regimen 
(Harri et al., 1999).   
Although our studies show that CYP1A1 KO mice exhibited attenuated 
vasodilation to EPA and DHA in the aorta and mesenteric arterioles, these studies were 
carried out without any luminal flow, thereby not mimicking in vivo conditions that 
incorporate flow mediated dilation (FMD).  It will be logical therefore for future studies to 
be conducted under varied degrees of luminal flow, since CYP1A1 has been demonstrated 
to be inducible by physiological levels of shear stress (Han et al., 2008; Conway et al., 
2009).  It is plausible we might expect to see even wider differences in vasodilation 
responses to n-3 PUFAs; EPA and DHA under flow conditions. 
In addition to elucidating the contribution of CYP1A1 to shear induced 
vasorelaxation, it would be necessary to determine also the concentrations of n-3 PUFA 
metabolites from CYP1A1 metabolism of n-3 PUFAs in plasma and red blood cells, and 
also following treatment with diets enriched in n-3 or n-6 PUFAs.  Since our data suggests 
that differential level of metabolites may drive the hypertension in CYP1A1 KO mice, 
using liquid chromatography–mass spectrometry (LC/MS/MS), we could measure these 
metabolites.  Additionally, since diastolic BP is significantly elevated across 24 hr period in 
CYP1A1KO mice, this could suggest that CYP1A1 metabolism of n-3 PUFA contributes 
to maintaining peripheral vascular resistance.  Future studies that assess cardiac output 
and stroke volume could be done to confirm if peripheral vascular resistance is altered in 
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the absence and presence of n-3 or n-6 PUFA supplementation in CYP1A1 WT and KO 
mice.   
Furthermore, it would be very insightful to elucidate the contribution of CYP1A1 
in maintaining membrane potential in vascular endothelial cells and vsmc, in the presence 
or absence of n-3 or n-6 PUFAs.  Endothelial and vsmc could be isolated from CYP1A1 
WT and KO mice and patch clamp experiments conducted to determine membrane 
potential prior to, and following treatment with n-3 or n-6 PUFAs.  These studies could 
also be repeated in the presence or absence of inhibitors of BK and Kv membrane 
channels.  This information will help determine the contribution of CYP1A1 to the 
hyperpolarization of the plasma membrane in general and elucidate further, alternative 
mechanisms of PUFA-mediated vasodilation in particular.  
While the role of CYP1A1 in BP regulation and the cardiovascular system in 
general is not clearly understood, it is noteworthy that several polymorphisms in the 
CYP1A1 gene exist in the human population.  For example, a common allelic variant of 
human CYP1A1 (Ile462Val) was shown to metabolize EPA in a different pattern, and the 
catalytic efficiency of this polymorphism for hydroxylation was five times higher, while 
that for epoxidation was twice higher than that of CYP1A1 WT (Schwarz et al., 2005).   
This suggests that CYP1A1 metabolism of n-3 PUFAs could contribute to differences 
between individuals in the production of beneficial physiologically active PUFA 
metabolites in the cardiovascular system. 
In summary, the nutritional benefits of n-3 PUFAs to the cardiovascular system 
remain not fully understood.  Nonetheless, our data demonstrate a BP lowering effect of 
n-3 PUFAs in CYP1A1 KO mice.  This suggests that n-3 PUFA-enriched diets could 
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contribute in lowering BP in hypertensive human subjects.  Regardless of the BP lowering 
effects of n-3 PUFAs, our study also demonstrates that n-3 and n-6 PUFAs lower 
triglycerides levels, and overall, this is beneficial to cardiovascular human health.  More 
clinical trial studies could be conducted to determine the amount and benefits of daily 
intake of n-3 PUFAs as supplements in humans, as a protection strategy against 
cardiovascular diseases.   
Currently, the American Heart Association (AHA) recommends 1 g 
EPA+DHA/day for patients with known coronary heart disease (CHD).  Additionally, for 
individuals with no CHD, the AHA recommends the consumption of two oily fish meals 
per week, which would provide 400–500 mg EPA+DHA/day (Kris-Etherton et al., 2002). 
However, if fish meals are not desirable, fish supplements as capsules could also be taken.  
It is recommended that fish supplements as capsules be labeled as ‘molecularly distilled’ 
since this process removes polychlorinated biphenyls contaminants.   
In summary, as show by our data herein, 17,18-EEQ and 19,20-EDP will be 
excellent and potential anti-hypertensive candidates.  It is important therefore, for future 
studies to look at clinical trials of CYP1A1 metabolites of n-3 PUFAs; 17,18-EEQ and 
19,20-EDP as anti-hypertensives, and the development of stable analogues of these 
metabolites to treat long-term resistant hypertension. 
The conclusion from our study is that the AHR and its downstream target gene, 
CYP1A1, regulate BP through different pathways and involve the perivascular adipose 
tissue (PVAT).  Our findings show that loss of AHR in the endothelium resulted in a 
hypotensive phenotype, consistent with the BP phenotype of the global AHR KO mouse, 
independent of NO.  Additionally, the hypotension was associated with reduced Ang II 
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responses ex vivo, in the presence of PVAT.  This suggests that loss of AHR in the 
endothelium alters paracrine signaling in the adipose tissue and supports a role for the 
PVAT in contributing to blood pressure regulation.  Although AHR is deleted in 
endothelium, CYP1A1 is still expressed in the adipose tissue and could also contribute to 
the pro-hypotensive effects seen in the ECahr
-/-
 mice.  Our study further show that global 
deletion of CYP1A1, in contrast, resulted to a hypertensive phenotype associated with 
reduced vasorelaxation to EPA and DHA.  The elevated BP was independent of NO, 
suggesting that CYP1A1 metabolism of n-3 PUFAs contributes to BP regulation by the 
production of stereospecific products that exhibit vasodilatory properties.  However, our 
results also show that loss of CYP1A1 could be compensated by other vascular P450 
epoxygenases in the presence of n-3 PUFA substrate bioavailability.  Although CYP1A1 
was globally deleted, n-3 PUFA supplementation was shown to normalize BP in CYP1A1 
KO mice to WT levels via a NO-dependent mechanism.  It is plausible that the global 
deletion of CYP1A1 including in the PVAT, contributes to a pro-hypertensive phenotype 
in the CYP1A1 KO mice.  In conclusion, although AHR is deleted in endothelium, adipose 
CYP1A1 could contribute to the hypotension seen in the ECahr
-/-
 mouse.  In contrast, the 
vasodilatory benefits of CYP1A1 including contributions from the PVAT is lost, 
contributing to an elevated BP as seen in the CYP1A1 KO mouse. 
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